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Abstract 
HYBRID PET/MRI NANOPARTICLE PROBE DEVELOPMENT AND MULTI-MODAL IMAGING 
By David Blair Hoffman, BS 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in Medical Physics at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013 
Director: Jamal Zweit PhD, DSc 
Professor, Department of Radiology 
The development of hybrid PET/MRI imaging systems needs to be paralleled with the 
development of a hybrid intrinsic PET/MRI probes.  The aim of this work was to develop and 
validate a novel radio-superparamagnetic nanoparticle (r-SPNP) for hybrid PET/MRI imaging.  
This was achieved with the synthesis of superparamagnetic iron oxide nanoparticles (SPIONs) 
that intrinsically incorporated 59Fe and manganese iron oxide nanoparticles (MIONs) that 
intrinsically incorporated 52Mn.  Both [59Fe]-SPIONs and [52Mn]-MIONs were produced through 
thermal decomposition synthesis.  The physiochemical characteristics of the r-SPNPs were 
assessed with TEM, DLS, and zeta-potential measurements, as well as in imaging phantom 
studies. The [59Fe]-SPIONs were evaluated in vivo with biodistribution and MR imaging studies.  
The biodistrubution studies of [59Fe]-SPIONs showed uptake in the liver.  This corresponded 
with major MR signal contrast measured in the liver. 52Mn was produced on natural chromium 
through the 52Cr(p,n)52Mn reaction.  The manganese radionuclides were separated from the target 
material through a liquid-liquid extraction.  The αVβ3 integrin binding of [52Mn]-MION-cRGDs 
was evaluated with αVβ3 integrin solid phase assays, and the expression of αVβ3 integrin in 
U87MG xenograft tumors was characterized with fluorescence flow cytometry.  [52Mn]-MION-
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cRGDs were used for in vivo PET and MR imaging of U87MG xenograft tumor bearing mice.  
PET data showed increased [52Mn]-MION-cRGD uptake compared with untargeted [52Mn]-
MIONs.  ROI analysis of PET and MRI data showed that MR contrasted corresponded with PET 
signal. Future work will utilize [52Mn]-MION-cRGDs in other tumor models and with hybrid 
PET/MRI imaging systems. 
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Chapter 1 
1. Introduction 
Recent development of hybrid PET/MRI imaging systems has not yet been paralleled with the 
development of a truly hybrid intrinsic PET/MRI probe.  This work has created a novel radio-
intrinsic nanoparticle probe for hybrid PET/MR imaging.  This was accomplished with a 
manganese iron oxide nanoparticle (MION) that intrinsically incorporates the PET imaging 
radionuclide, 52Mn.  This probe brings to molecular imaging a single imaging agent that is 
detectable with PET and MRI, in order to combine the complementary strengths of each 
modality. 
1.1. Objectives 
The aim of this research is to develop, characterize, and evaluate a hybrid PET/MR nanoparticle 
probe.  The specific objectives of this project are: 
1. Synthesize a radioactive superparamagnetic nanoparticle (r-SPNP) that intrinsically 
incorporates a positron emitting radionuclide for PET signal and MR imaging. 
2. Investigate a surface coating appropriate for in vivo imaging. 
3. Evaluate the nanoparticle’s physicochemical characteristics for both PET and MR 
imaging.  
4. Conjugate the r-SPNP surface coating with cyclo(Arg-Gly-Asp) targeting peptide 
(cRGD) and image the biological expression of αVβ3 integrin in vivo. 
5. Quantify PET signal and relate it to the MR contrast resulting from the nanoparticle 
probe. 
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1.2. Strategy 
This project exploits the radiometal, 52Mn, which gives PET signal through its positron emission 
and can be intrinsically incorporated into MION structures to give MR contrast.  In this research, 
monocrystalline SPIONs and MIONs were produced through high temperature thermal 
decomposition synthesis.  Intrinsically incorporated into these nanoparticles are two 
radionuclides.  First 59Fe [ t1/2 = 44.5 days, γ = 1099 keV (56%) and 1292 keV (44%)] was 
incorporated into a SPION, as a surrogate for 52Fe.  Its long half-life and gamma emission were 
suitable for developing the incorporation chemistry and for use in biodistribution studies.  For 
PET imaging, 52Mn (t1/2 = 5.591 days, 29.6% β+) was incorporated into MIONs and utilized in 
imaging studies.  52Fe was not utilized for incorporation and PET imaging studies, because to 
achieve the 55Mn(p,4n)52Fe reaction, 50-60 MeV protons are needed, and the cyclotron facilities 
needed for this energy range were not available. These r-SPNPs were coated with a multidentate 
catechol-based polyethylene glycol oligomersin, which can be modified and conjugated to 
targeting moieties.  The targeting molecule chosen to for conjugation with the 52Mn-MIONs was 
cyclo(Arg-Gly-Asp) peptide, which has been previously used to target the αVβ3 integrin with 
PET and MRI.  The use of these cRGD conjugated 52Mn-MIONs for in vivo targeted molecular 
imaging was demonstrated in U87MG xenograft tumor bearing nude mice. 
1.2.1. Extrinsically vs. Intrinsically Radio-labeled Nanoparticles 
There are two main approaches to incorporate a radionuclide into nanoparticles, as shown in 
Figure 1.  The first strategy is to externally radiolabel nanoparticles using a linker, such as radio-
chelate complexes.  There are potential limitations of external labeling strategies.  The external 
label changes the chemical structure of the nanoparticle probe, which may change its in vivo 
pharmacokinetics.  The external label is on the surface of the nano-structure and is exposed to 
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chemical and enzymatic activity that may separate the radionuclide from the nanoparticle.1  This 
could compromise the label’s usefulness for multi-modal imaging.  The second strategy, utilized 
in this work, intrinsically incorporates the radionuclide into the core structure of the nanoparticle. 
This will ensure effective shielding of the radionuclide within the nano-construct, thereby 
providing a pharmacokinetic profile indicative of the overall nanoparticle.  Additionally, this will 
simplify the surface coating chemistry and offer a greater surface area for conjugation of the 
targeting moiety.  The intrinsic incorporation of the radionuclide has limitations as well.  Radio-
intrinsic nanoparticles must be synthesized new for each imaging study, as opposed to an 
extrinsic chelator, where the imaging agent can be synthesized and stored for a time and 
radionuclide can then be produced and chelated as needed.  Additionally, the synthesis of the 
rSPNPs cannot be scaled down indefinitely. This means that in order to manipulate the radio of 
activity to NP mass, increasingly large activities must be utilized. 
 
Figure 1: The radioactive chelator model (A) externally labels the nanoparticle, while the radio-intrinsic model (B) 
internally incorporates the radioactivity in the nanoparticle. 
1.2.2. Radio-intrinsic Superparamagnetic Nanoparticle 
For the intrinsic inclusion of radionuclides into the nanoparticle structure, 59Fe and 52Mn were 
used for incorporation.  These radionuclides are chemically identical to the iron and manganese 
 4 
 
used for the SPION and MION structures.  While other imaging radionuclides, such as 89Zr, 
64Cu, or 55Co, are candidates for incorporation, the manganese and iron radionuclides utilized in 
this project do not change the chemical structure or physical characteristics of the nanoparticle.  
This strategy lessens the possibility of the radio-incorporation damaging the MR contrast 
characteristics.  Additionally, this approach avoids the possibility of un-chelated moieties being 
present on the nanoparticle coating, which could increase the nanoparticles binding with plasma 
proteins, increase the nanoparticle’s size, and change the pharmacokinetic profile.  
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Chapter 2 
2. Background 
Cancer is a family of over 200 diseases associated with the disregulation of cellular proliferation 
and growth.  Medically known as malignant neoplasm, cancer is the leading cause of death in 
economically developed countries and the second leading cause of death in developing countries, 
with an estimated 12.7 million cancer cases and 7.6 million cancer deaths worldwide in 2008.2 
Major efforts are being made to gain insights into the pathology, and treatment of these diseases. 
Research into the behavior of malignant tissues aids in developing disease treatment, by 
revealing the molecular biology and biochemistry of cancerous cells.  
In order to develop into cancer, potentially malignant cells must gain a number of biological 
capabilities, including sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis.3  The successful treatment of cancer is greatly aided by detecting cancer cells early in 
this process.  Additionally, anti-cancer therapy has been progressed by the implementation of 
personalized medicine, where a patient’s treatment is tailored to the unique set of molecular 
aberrations driving his/her disease.4  Medical imaging is an important clinical tool to achieve 
both of these goals. 
2.1. Medical Imaging of Cancer 
A number of imaging modalities are used in the detection and characterization of cancer.  
Anatomical imaging techniques are used for diagnosis, surgical guidance/follow-up, and 
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treatment monitoring.  These anatomical imaging modalities include radiography, computed 
tomography (CT), ultrasound (UT), and MRI.  One of the major challenges to anatomical 
imaging of cancer is low contrast.  Malignant tissue often has similar physical properties to 
normal tissue, making the detection and delineation of small tumors or metastases difficult.  
Additionally, the sub-clinical disease or microscopic extent, including micro-metastases micro-
extensions, often will not give sufficient contrast for detection. 
2.2. Molecular Imaging of Cancer 
The clinical effort for early detection of cancer and the application of personalized anticancer 
therapies has been aided by the development of molecular imaging.  Drug discovery and 
development has also been assisted with the application of molecular imaging technology for 
characterizing novel drug pharmacokinetics.5  Furthermore, research into the molecular biology 
and biochemistry has been advance by the application of molecular imaging.6  A number of 
imaging modalities are utilized in molecular imaging.  A number of these modalities and some of 
their characteristics are described in Table 1.  This project focuses on PET and MRI, which are 
detailed further in Sections 2.3 and 2.4. 
Table 1: Characteristics of medical imaging modalities that have molecularly targeted imaging agents or non-
targeted agents. 
Modality Advantages Disadvantages Imaging 
agent 
Clinical examples 
Computed 
tomography 
• Unlimited depth 
penetration 
• High spatial resolution 
• Whole-body imaging 
possible 
• Short acquisition time 
(minutes) 
• Moderately expensive 
• Anatomical imaging 
• Radiation 
exposure 
• Poor soft-
tissue contrast 
• Probably not 
used for 
molecular 
imaging; 
currently only 
• Barium 
• Iodine 
• Krypton 
• Xenon 
• Tumor perfusion 
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anatomical and 
functional 
imaging 
Positron 
emission 
tomography 
• Highly penetrating 
signal 
• Whole-body imaging 
possible 
• Quantitative molecular 
imaging 
• Can be combined with 
CT or MRI for 
anatomical information 
• Radiation 
exposure 
• Expensive 
• Low spatial 
resolution (1–
2 mm pre-
clinical, 6-7 mm 
clinical) 
• Long 
acquisition 
times (minutes 
to hour) 
• 
11C 
• 
18F 
• 
64Cu 
• See Table 2 
• 
18F-FDG-PET 
for cancer staging 
• Diagnosis of 
various diseases 
(see Table 2) 
Single 
photon-
emission 
computed 
tomography 
• Highly penetrating 
signal 
• Whole-body imaging 
possible 
• Quantitative molecular 
imaging 
• Theranostic: can 
combine imaging and 
radiotherapy 
• Can be combined with 
CT for anatomical 
information 
• Radiation 
exposure 
• Low spatial 
resolution (0.3–
1 mm 
preclinical, ~1 
cm clinical) 
• Long 
acquisition time 
• 
99mTc 
• 
123I 
• 
111In 
• 
177Lu 
• Diagnosis of 
various diseases 
• Radiotherapy for 
NHL: 90Y-Bexxar 
or 131I-Zevalin 
• Radiotherapy of 
thyroid carcinoma 
with 131I-iodide 
Magnetic 
resonance 
imaging 
• Highly penetrating 
signal 
• Whole-body imaging 
possible 
• No ionizing irradiation 
• Excellent soft-tissue 
contrast 
• High spatial resolution 
• Expensive 
• Long 
acquisition time 
(min-hours) 
• Limited 
sensitivity for 
detection of 
molecular 
contrast agents 
• Gadolinium 
(Gd3+) 
• Iron oxide 
particles 
• Manganese 
oxide 
• 
19F 
• SPIOs for 
detection of 
lymph node 
metastases of 
prostate cancer 
• Characterization 
of focal hepatic 
lesions 
• Perfusion 
imaging of the 
heart 
Magnetic 
resonance 
spectroscopy 
• Whole-body imaging 
possible 
• No ionizing irradiation 
• Expensive 
• Long 
acquisition time 
(min-hours) 
• Low 
sensitivity 
• Choline 
• Creatine 
• Lactate 
• Lipids 
• Polyamines 
• N-acetyl-
• Metabolite 
levels in brain 
tumors 
• Treatment 
monitoring of 
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aspartate Alzheimer’s 
Ultrasound • No ionizing irradiation 
• Real-time imaging/short 
acquisition time (min) 
• High spatial resolution 
• Can be applied 
externally or internally 
(endoscopy) 
• Inexpensive 
• Highly sensitive 
• Clinical 
whole-body 
imaging not 
possible 
• Contrast 
agents currently 
limited to 
vasculature 
• Operator 
dependency 
• Contrast 
micro-
bubbles 
• Characterization 
of focal liver 
lesions 
• Echocardiograp
hy 
• Tumor perfusion 
of cancer 
Optical • No ionizing irradiation 
• Real-time imaging/short 
acquisition time (sec-
min) 
• Relatively high spatial 
resolution 
• Can be applied 
externally or internally 
(endoscopy) 
• Inexpensive 
• Highly quantitative and 
sensitive 
• Multiplexing 
• Limited depth 
penetration 
(≤1 cm) 
• Clinical 
whole-body 
imaging not 
possible 
• Fluorescent 
molecules 
and dyes 
• Light-
absorbing 
nanoparticles 
• Quantum 
dots 
• OCT imaging of 
artherosclerosis 
• OCT imaging 
for colonoscopy 
screening 
• Raman imaging 
of skin cancer 
2.3. Positron Emission Tomography 
Positron emission tomography is a molecular imaging technique that has wide research and 
clinical management applications, particularly in cancer.7 PET has made large contributions to 
molecular imaging with the application of a variety of radiotracers.  A radiotracer is a chemical 
structure that incorporates a positron emitting radionuclide.  A number of PET imaging 
radionuclides are described later, in Section 2.3.2.  The PET pharmaceutical is introduced to a 
living organism through a variety of methods, mainly through intravenous injection, and the 
subject is imaged during or sometime after administration.  The PET image shows the spatial 
distribution and concentration of the probe with respect to time. The body’s handling and 
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distribution or pharmacokinetics of the PET radiotracer depends on the chemical structure, and 
affect the final PET image. 
PET radiotracers have been developed and utilized for studying brain and heart function, but 
most widely in oncology.8  Specifically, PET pharmaceuticals have been developed that target 
malignant tumors for the localization and characterization of these cancers.  The tracers function 
principally by targeting physiological processes or conditions that are up-regulated as a 
consequence of malignant involvement, such as perfusion, bone deposition, glucose metabolism, 
cell proliferation, or antigen and receptor expression. Additionally, the kinetics anti-tumor drugs 
have been evaluated through molecular imaging studies.9 The strategy for drug pharmacokinetic 
evaluation has become widely utilized in novel drug development. Table 2 details a number of 
PET tracers used for clinical imaging of disease. 
Table 2: PET tracers used for the imaging of disease. 
Medical imaging Target Radiotracer(s) Clinical applications 
Oncological 
imaging 
Protein synthesis 11C-methionone, 11C-
tyrosine 
Protein synthesis in 
tumors 
Glucose transporter 18F-FDG Glucose metabolism 
in tumors 
Choline transporter 11C-choline Tumor phospholipid 
synthesis 
Thymidine uptake in 
DNA/RNA synthesis 
18F-FLT, 18F-FMAU; 
18F-FU 
Tumor cell 
proliferation 
Phosphatidylserine 124I-annexin-V Apoptosis 
αVβ3 integrin 18F-galacto-RGD Tumor angiogenesis 
HSV1-tk 18F-FHBG Suicidal gene therapy 
Hypoxia 18F-FMISO; 64Cu-, 
60Cu-ATSM 
Tumor hypoxia 
Somatostatin receptor 64Cu-TETA-octreotide Neuroendocrine 
tumors 
Oestrogen receptor 18F-FES Breast cancer 
Androgen receptor 18F-FDHT Prostate cancer 
Bone deposition 18F- Oncology 
Perfusion H215O, C15O2, 13NH3, Oncology,  Brain 
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11CO2, 82Rb Ischemia 
Cardiovascular 
imaging 
Cell metabolism 11C acetate Cardiac metabolism 
Fatty acid metabolism 11C palmitate Ischaemia 
Adrenergic 
neurotransmission 
11C metahydroxy-
ephedrine 
Heart failure 
Cardiac sympathetic 
neurons 
18F norephinephrine Cardiac sympathetic 
innervation 
Neurological 
imaging 
Dopamine post synaptic 
receptors 
11C raclopride Schizophrenia, 
addiction 
β-amyloid 11C-PIB Alzheimer’s disease 
NK-1 receptor 18F-SPARQ; 11C-
R116301 
Depression, anxiety 
Dopamine transporter 18F-FECNT Schizophrenia, 
addiction 
Dopamine metabolism 18F-DOPA Schizophrenia, 
addiction 
2.3.1. Decay, Annihilation, and Coincidence Detection 
While inside the body, the radiotracer will undergo radioactive decay.  A portion of those decays 
yield positrons, which have a kinetic energy spectrum that dependents on the radionuclide.  This 
kinetic energy will be lost by the positron as it interacts traveling a short distance through tissue.  
This distance will be discussed further in Section 2.3.2. Once the positron has lost most of its 
kinetic energy, it will annihilate with an electron.  This annihilation produces two 511 keV 
gamma rays, emitted almost exactly 180º away from each other, as shown in Figure 2. The 
deviation from 180º is a result of the combined momentum of the annihilated electron and 
positron, and it is typically 0.25º.  The distance traveled by the positron from the decay event to 
the annihilation event and the acolinearity of the annihilation gamma rays represent losses in 
spatial resolution that cannot be recovered during image reconstruction. 
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Figure 2: A positron emitting radionuclide decays and yields a positron that travels a distance through tissue and 
annihilates with an electron.  This emits two 511 keV photons that exit the body and are detected by the array of 
scintillation crystal for image reconstruction. 
The annihilation gamma photons pass through the body and those that emerge can be registered 
by a detector array of scintillation crystals arranged in opposing banks, as shown in Figure 2.  
The gamma ray interactions are paired when one ray of the correct energy is detected within a 
short time interval (coincidence window) of another ray detection.  In the case of these “true” 
detections, the gamma ray pairs are then designated as originating from the same annihilation 
that occurred on a “line of response” (LOR) between the two detectors.  These LORs are stored 
as projections. 
There is a probability that one or both of the annihilation gamma rays will interact with the tissue 
before exiting the body (scatter or attenuation) or exit the scanner without being detected.  When 
this occurs, coincidence events other than “true” detections can be recorded.  As shown in Figure 
3, this can result in random and scattered detections.  In scattered coincidence events, one or both 
of the gamma rays are scattered within the subject, but both are detected within the coincidence 
window with the appropriate energy.  The non-perfect time and energy resolution of PET 
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scanners allow for the detection of scattered events.  Random coincidence events occur when 
two photons from different annihilation events are detected and recorded.  This is a result of the 
finite temporal resolution of PET scanners. 
 
Figure 3: A) True coincidence detection occurs when the two gamma rays from an annihilation event exit the body 
and are detected by the scintillation crystals within the energy and time windows allowed for coincidence.  B) If one 
or both of the photons are scattered, but are still detected within the time and energy windows, then a scattered 
coincidence has occurred.  C) When two photons from different annihilation events are detected, a random 
coincidence has occurred. 
Scattered and random events result in incorrectly registered annihilations events.  This leads to 
decreased image contrast and increased noise.  Corrections are applied to the LORs for the 
scattered and random fractions, as well as detector dead time, attenuation, and variations in 
detector element sensitivity.  From this corrected emission data, PET images are reconstructed.  
Reconstruction can be accomplished with analytical approaches, such as filtered back projection 
(FBP) or using iterative methods, such as ordered subsets expectation maximization (OSEM).10 
2.3.2. PET Radionuclides 
A number or radionuclides are used for PET tracers.  Among them are several biologically 
relevant organic radionuclides that can be incorporated into organic compounds.  These organic 
radionuclides have relatively short half-lives that require rapid radiochemistry and onsite 
cyclotron production or immediate delivery.  The characteristics of a variety of these organic 
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PET radionuclides are shown in Table 3.11 Note that while 18F is not organic, it is used to replace 
a hydrogen atom in many organic compounds. 
Table 3: The characteristics of organic PET radionuclides. 
Nuclide Half-life Decay Modes Maximum 
positron energy 
(MeV) and 
yield (%) 
Production 
11C 20.4 mins EC, β+ 0.961 (99.8%) 14N(p,α)11C 
13N 9.96 mins EC, β+ 1.2 (99.8%) 16O(p, α)13N 
15O 2.04 mins EC, β+ 1.73 (99.9%) 15N(p,n)15O 
14N(d,n)15O 
18F 109.8 mins EC, β+ 0.634 (96.7%) 18O(p,n)18F 
20Ne(d, α)18F 
Another group of PET radionuclides are inorganic atoms that tend to have longer half-lives.  This 
makes them accessible for more complex radiochemistry and applicable to use in tracers with 
slower pharmacokinetics, such as macromolecules, and in longitudinal studies.  Some of these 
radionuclides are produced by generator systems and are shown in Table 4.12,13,14  Other 
cyclotron produced PET radionuclides are shown in Table 5.15 These radiometals have been 
widely utilized in tumor imaging, as well as therapy through α, β-, and Auger electron 
emission.16 
Table 4: The characteristics of various inorganic generator produced PET radionuclides. 
Nuclide Half-life Decay Modes Maximum 
positron energy 
(MeV) and 
yield (%) 
Production 
62Zn/62Cu 9.19 hrs /  
9.74 mins 
EC, β+ 2.93 (97.4%) 63Cu(p,2n)62Zn 
68Ge/68Ga  288 days / 
68 mins 
EC, β+ 1.899 (87.7%) 
0.821 (1.2%) 
68Ga(p,2n)68Ge 
82Sr/82Rb 25.6 days / 
1.27 mins 
EC, β+ 3.38 (95.5%) 85Rb(p,4n)82Sr 
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Table 5: The characteristics of various inorganic cyclotron produced PET radionuclides. 
Nuclide Half-life Decay Modes Maximum 
positron energy 
(MeV) and 
yield (%) 
Production 
52Mn(17) 5.6 days EC, β+ 0.575 (29.6%) 52Cr(p,n) 52Mn 
52Fe(18) 8.275 hrs EC, β+ 0.804 (55.5%) 52Cr(3He,2n) 52Fe 
52Cr(α,3n) 52Fe 
55Mn(p,4n) 52Fe 
55Co(19) 17.54 hrs EC, β+ 1.950(45.7%) 
1.431(3.05%) 
1.311(43.7%) 
56Fe(p,2n)55Co 
64Cu 12.7 hrs EC, β+, β-  0.653 (17.4%) 62Ni(p,n)64Cu 
67Br 16.2 hrs EC, β+ 3.941 (54.7%) 76Se(p,n)76Br 
86Y(20) 14.74 hrs EC, β+ 3.141 (31.9%)* 86Sr(p,n)86Y 
89Zr(21) 78.41 hrs EC, β+ 0.897 (22.3%) 89Y(p,n)89Zr 
124I 4.18 days EC, β+ 2.138 (23.0%) 126Te(p,3n)124I 
*Many β+ decays are possible for 86Y, with maximum energy of 3.131 MeV, average energy of 0.664 MeV, and 
total yield of 31.9%. 
As discussed earlier in Section 2.3.1, when imaging PET radionuclides, after the decay event, the 
emitted positron will travel a distance, while losing kinetic energy, before annihilating with an 
electron.  The length of the mean free path of these positrons results in a loss of spatial 
resolution.  For all PET radionuclides, a greater the positron energy causes a longer the mean 
free path, and the greater loss in spatial resolution.  Therefore, the maximum positron energy is 
an important characteristic of all PET radionuclides. 
2.4. Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a powerful 3-dimensional imaging technique that has 
become widely used for medical imaging.  MRI provides good soft tissue contrast and sub-
millimeter spatial resolution, while avoiding patient exposure to ionizing radiation.  Its 
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anatomical imaging applications include cardiac imaging, neuroimaging, musculoskeletal 
imaging, to angiography.22 
During an MRI scan, the subject is placed in the bore of a powerful magnet with an external 
magnetic field, B0. This aligns the net magnetization of the tissues of the patient in the “z” 
direction, which in the direction of the length of the bore.  The aligned particles precess around 
the “z” direction at the Larmor frequency, shown in Equation 1, where γ is the gyromagnetic 
ratio of the particles of interest (42.58 MHz/T for 1H). 
1 f = γB  
The main magnetic field strength, B0, commonly ranges from 0.2 to 7 T.  Higher strength fields 
result in higher image signal to noise ratio (SNR) but also result in reduced radiofrequency field 
(RF) homogeneity and increased specific absorption rate (SAR). 
When the patient is MR imaged, a short RF pulse, tuned to the Larmor frequency, excites the 
spins of the precessing atoms out of the longitudinal state into the transverse plane, as shown in 
Figure 4.23  The spins eventually return to equilibrium with B0 at a rate that is dependent on the 
excited molecules.  The return to the longitudinal state from the transverse plane is described 
with the relaxation parameters, R1 and R2, which are described with more detail in Section 2.4.1. 
R1 and R2 are the reciprocals of T1 and T2 respectively. 
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Figure 4: The precession, excitation, and relaxation of spins in MRI.  The “laboratory frame” is the static reference 
frame of the MRI scanner with the z-axis oriented along the bore of the main magnetic.  The rotation frame 
precesses about the z-axis of the laboratory frame at the Larmor frequency.  A) The atoms of the imaged tissue 
precess around the magnetic field at the Larmor frequency. B) An excitation pulse of RF excites a slice of the tissue 
into the transverse plane. The net magnetization relaxes growing in the longitudinal direction, discribed by the 
parameter T1, and decaying away from the transverse plane as described by the parameter T2. 
During the relaxation, the precessing nuclei emit RF that is received either by the large body coil 
that induced the excitation or by a smaller local coil for increased SNR.  A gradient field varies 
during the imaging sequence to select different regions during excitation and read out to give the 
signal spatial information. 
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2.4.1. Relaxation Parameters 
The magnitude of the signal emitted by the nuclei during an MRI sequence depends on the 
relationship between the relaxation parameters (T1 and T2) and the sequence parameters, 
repetition time (TR) and the echo time (TE).  TR is the time between excitations and TE is the 
time between excitation and the start of signal acquisition.  For T2-weighted imaging, a TR 
much longer than T1 is used to minimize the effect of T1, while a TE about as long at T2 is used 
to show differences in T2 decay. For T1-weighted imaging, a sequence with TR shorter than T1 
is used so the longitudinal magnetization does not entirely recover before the next repetition, and 
a short TE is used to prevent T2 contrast.  Sequences with long TR and short TE result in proton-
density weighted images. 
2.4.2. Contrast Agents 
Exogenous contrasts agents are used in MRI to give contrast to tissues or structures that would 
otherwise be difficult to visualize.  The most widely used family of contrast agents are 
gadolinium based.  Gadolinium has seven unpaired electrons, which results in it being strongly 
paramagnetic.  The gadolinium atoms act as small magnetic field inhomogeneities, which 
decreases T1 and T2 relaxation times of protons around the molecule.  At clinically used 
concentrations, about 0.1 mM, the decreased T1 is the predominant effect, resulting in 
gadolinium uptake appearing brighter in T1-weighted scans.  At concentrations greater than 1 
mM, the decreased T2 becomes the predominant effect on the image, and the gadolinium results 
in reduced MR signal.  Gadolinium itself is toxic in elemental form, so it is chemically chelated 
to ligands, such as diethylene-triamine penta-acetic acid (DTPA), that reduce the biological 
toxicity.  Due to the relatively high concentrations needed for MR contrast, gadolinium is 
generally used as a non-targeted imaging agent, taken up by brain lesions due to disruptions in 
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the blood brain barrier, or for perfusion and heart function imaging. The second family of MRI 
contrast agents is iron oxides, which will be detailed in Section 2.6.  Iron oxides mainly reduce 
T2, so they are negative contrast agents in T2-weighted scans.  They are FDA approved for the 
imaging of liver lesions. 
2.5. Hybrid Imaging 
Medical imaging techniques have a variety of advantages and disadvantages,8 and hybrid 
scanners and imaging probes have been developed combining multiple imaging modalities.  
With hybrid imaging, two or more imaging techniques are incorporated into a single scanner.  
Images from each modality are acquired either simultaneously or consecutively.24  The resulting 
image data sets are co-registered, and in some cases, one image set is utilized in the 
reconstruction of the other.25 A hybrid x-ray CT-fluorescence system has been developed, which 
not only gives the anatomical back drop from the CT scan, but also gives useful prior 
information for the reconstruction of the fluorescence molecular tomography.26  Hybrid optical 
and MRI systems are being developed that similarly give anatomical detail and also identify the 
boundaries between tissues with different optical properties.27  Hybrid nuclear medicine and 
optical scanners are used to simultaneously observe multiple molecular targets and bridge optical 
and radioactive imaging techniques.28  Hybrid x-ray and MR imaging systems combining 
fluoroscopy and a vertical gap MR scanner have been used to assist with a number of patient 
interventions.29  Photoacoustic tomography is a multi-modal imaging technology that uses laser 
light to cause thermal expansion in endogenous or externally administered chromophores.  This 
expansion causes an ultrasonic pressure-wave that is received by an ultrasound transducer, and 
this signal can be co-registered onto an ultrasound image produced by the same system.30 
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2.5.1. PET/CT 
PET offers three-dimensional high sensitivity to imaging molecules that incorporate a positron 
emitting radionuclide, but has low spatial resolution and poor anatomical detail.  To address the 
lack of anatomical information, a dual modality approach is commonly used, which pairs a PET 
scan with a computed tomography scan.31,32  CT scanners use kilo-voltage x-ray tubes to axially 
scan the patient with ionizing radiation and create a three-dimensional image based on each 
voxel’s electron density and atomic number.  By fusing the two scanners and the two images, 
one image is produced including both the molecular information of the PET image and the 
anatomical information of the CT image.  MRI is a useful tool in evaluating pharmacodynamics 
and PET can be used to study pharmacodynamics and pharmacokinetics in clinical development 
of innovative therapeutics.33,34 
2.5.2. PET/MRI 
Compared to CT, MRI offers better soft tissue contrast, more information, and no ionizing 
radiation dose. However, pairing it with PET has been difficult due to engineering challenges.  
Specifically, the magnetic field produced by a MRI scanner interferes with the movement of 
electrons within the photomultiplier tubes (PMTs) incorporated in a PET scanner.  The 
development of avalanche photodiodes (APDs) to replace the PMTs lead to the creation of 
PET/MRI scanning systems.35  These scanners integrate the PET scanner within the magnet of an 
MRI scanner, such that studies can be acquired simultaneously, rather than PET/CT scanners that 
have a back-to-back design for consecutive scans.36   
PET/MRI scanning systems, offer a number of advantages over PET/CT.  The simultaneous 
acquisition of MR and PET images allows for faster imaging and higher patient through-put.  
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MRI allows for functional and metabolic imaging and better soft tissue contrast than CT.  
Additionally MRI does not contribute to the ionizing radiation dose of the patient.37  
Interestingly, operating a PET scanner within the magnetic field of a MRI scanner has the 
additional benefit of shortening the mean free path of the positrons before annihilation, thereby 
increasing PET spatial resolution.38  The strengths of combining PET and MRI, along with the 
development of the simultaneous PET/MRI scanner, has lead to its use in research and clinical 
molecular and neurological imaging.39  Additionally, this combination of imaging modalities 
offers the opportunity to match the high sensitivity of PET with the high resolution of MRI in 
imaging probe detection.  Hybrid PET/MRI systems have become increasingly utilized in 
clinical and pre-clinical research worldwide. 
2.6. Superparamagnetic Iron Oxides 
Superparamagnetic iron oxide (SPIO) contrast agents have been used clinically as MRI contrast 
agents for over a decade.  They are strong enhancers of proton relaxation, but unlike gadolinium, 
they are superparamagnetic.  Superparamagnetism occurs as the crystal-containing regions of 
unpaired spins are large enough they are thermodynamically independent, single domain 
particles.  Each domain’s net magnetic dipole is greater than that of its individual unpaired 
electrons. Without an external magnetic field (B0), the magnetic domains rotate from thermal 
motion and orient randomly.  When an external magnetic field is applied, the magnetic domains 
orient themselves with B0. Under these conditions, SPIOs mainly induce T2 relaxivity, and are 
used as negative contrast agents in T2-weighted images.  SPIO contrast agents have a wide range 
of physico-chemical properties that are dependent on the design of the particles.  Specifically, the 
size, charge, and coating of the particles affect their in vivo pharmacokinetics, and subsequently 
their application.40  Clinically used SPIO contrast agents are composed of a number of 
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superparamagnetic iron oxide crystalline structures and a coating and material.  The general 
formula of the crystalline structure Fe23+O3M2+O, where M2+ is a divalent metal ion such as iron, 
manganese, nickel, cobalt, or magnesium.41  Each crystal is surrounded by the coating material, 
often composed of dextran or PEG-phospholipid amphiphilic molecules or dopamine-based 
derivatives that protects the nano-structure from the in vivo surrounding environment. 
2.6.1. Applications 
SPIO contrast agents range in size from about 15 nm up to 3.5 um.  Their size affects their 
usefulness in different medical imaging applications.  The size of these particles is usually 
defined as hydrodynamic size as measured through dynamic light scattering.  The largest SPIO 
agents range in size from 300 nm to 3.5 um and are administered to patients orally to image the 
gastrointestinal lumen.  Smaller SPIO agents (60-120 nm) are used as clinical molecular imaging 
probes.  They are administered by either slow infusion or bolus injection.  These agents are 
principally used for lesion detection in the liver and spleen.  After intravenous administration, the 
SPIO agents are rapidly cleared from the blood and collected by the reticuloendothelial system 
(RES) cells of the liver and spleen.  Lesions are generally without RES cells, including 
phagocytes, and do not phagocytose the SPIOs and appear unchanged in MR images.  USPIO 
agents or “ultra-small” SPIOs are 20-40 nm in size are clinically used for metastatic lymph node 
detection and MR angiography (MRA).  Unlike larger SPIOs, these agents are not cleared from 
the blood as quickly and offer increased contrast in MRA.  Over time, they are collected by RES 
cells, including in lymph node monocytes and macrophages.  Lymph nodes that have metastatic 
disease lose these RES cells and do not take up the SPIO agents.42  Superparamagnetic iron 
oxide contrast agents are also clinically used for bone marrow imaging and perfusion imaging of 
the brain, myocardium, kidney, and tumor vasculature.43,44  Mono-crystalline superparamagnetic 
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iron oxide nanoparticles (SPIONs) differ from other SPIO contrast agents in their 
monocrystallinity.  With hydrodynamic sizes ranging from 2-20 nm, they are in the size range 
needed for target MR imaging.  Each particle is composed of a maghemite (γFe2O3) or magnetite 
(Fe3O4) core and an organic coating.  The maghemite crystal contains thousands of iron atoms 
and can generate MR signal contrast at concentrations orders of magnitude lower than 
conventional gadolinium chelates.45   
2.6.2. Mono-Crystalline Superparamagnetic Nanoparticles 
While SPIONs are not widely used in the clinic, their strong change in signal intensity, 
biodegradable iron composition, straightforward surface chemistry, and flexible magnetic 
properties make them popular for target MR imaging probe research.46  SPIONs have been used 
in vivo to image HER2/neu expression in NIH3T6.7 xenographic tumors by binding herceptin to 
the MION surface and to image angiogenesis through αvβ3 integrin expression in BT-20 
xenographic tumors by binding arginine-glycine-aspartate peptides to the SPION surface.47 By 
incubating SPIONs with 59Fe with in organic solvents, SPIONs have been labeled with a gamma 
emitting radionuclide for bimodal detection.48 Recently, cRGD targeted SPIONs extrinsically 
labeled with DOTA-64Cu were used to PET and MR image tumor integrin expression in vivo.49  
This nano-platform has additionally been conjugated with doxorubicin using a pH-sensitive 
hydrazone bond to achieve pH-responsive drug release.50  Tumor targeted SPIONs have been 
used in a short external alternating magnetic field to produce heat and deliver hyperthermia 
treatment to tumor bearing mice.51 SPIONs are becoming utilized for “cancer nanotheranostics,” 
which is a strategy that simultaneous images and treats cancer cells through the application of 
nanoparticles.52  While SPIONs have been utilized in this multitude of applications, the synthesis 
of these nanoparticles with ideal characteristics for in vivo imaging is still developing.  SPIONs 
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are promising tools in cancer imaging, drug delivery, and therapy.  Their MR contrast and 
multifunctional potential highlight their potential in molecular imaging and cancer treatment.53,54 
2.6.3. Synthetic Strategies 
SPIO production is achieved through three main families of chemical synthesis:  chemical 
precipitation, reactions in constrained environments, and high temperature methods.55  Chemical 
precipitation is the simplest and most well established method, where the SPIONs are created by 
co-precipitation of a mixture of ferrous and ferric salts.56  This reaction is achieved in an aqueous 
base and can be written as: 
Fe2+ + 2Fe3+ + 8OH- → Fe3O4 + 4H2O 
During synthesis, the iron ions can become oxidized before they precipitate.  This effect can be 
reduced, but not prevented, by precipitating under nitrogen protection.  This results in the 
simultaneous production of magnetite and maghemite nano-particles.   
Fe3O4 + 2H+ → γFe2O3 + Fe2+ + H2O 
Maghemite crystals exhibit lower mass magnetization than magnetite and are difficult to 
separate.  The size of the crystals can be manipulated by controlling the reaction pH, ionic 
strength, temperature, nature of salts, and Fe3+/Fe2+ ratio.57  The creation of crystal seeds 
simultaneous with crystal growth leads to disperse crystal size distribution. Chemical 
precipitation is depicted in Figure 5. 
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Figure 5: Chemical precipitation synthesis of SPIOs. A) Ferrous and ferric salts are dissolved aquiously in the 
presence of carbohydrates, such as dextran. B) Iron oxide crystals form during nucleation. C) The iron oxide crystals 
aggregate and are coated by the carbohydrates to form SPIOs. 
Reactions in constrained environments use structures to separate crystal growth from crystal seed 
creation.  These structures include water-swollen reversed micellar structures in nonpolar 
solvents, apoferritin protein cages, dendrimers, cyclodextrins, and phospholipid membranes that 
form vesicles with iron oxide nanoparticles serving as solid supports.23  Reversed micelles are 
good examples of how these structures are used to control iron oxide crystal size.  These micelles 
are formed by amphiphiles.  Amphiphiles are lipids that have both hydrophilic and hydrophobic 
parts.  These amphiphiles form colloidal micelles when in an aqueous environment.  In micelle-
forming lipids, the hydrophobic chains are oriented inward and the hydrophilic chains outward.  
Reverse micelles are similar, but have the hydrophilic chains oriented inward and the 
hydrophobic chains oriented outward.  They solublize water in non-polar media and form micro-
environments correct for SPION formation.58  The reverse micelles restrict the amount of iron 
salts available for crystal formation.  The size of the nanoparticles is controlled by the interplay 
between the lipid chain length and concentration, and solution pH and temperature.  Other 
strategies employ other structures that separate crystal formation and crystal growth.  In general, 
while these methods create more monodisperse crystal distribution, the reaction yield is reduced 
and the synthesis is not easily scaled up for industrial nano-particle production. 
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High temperature methods decompose iron complexes, such as Fe(Cup)3, Fe(CO)5, or Fe(acac)3, 
in the presence of surfactants and organic solvents.  At these high temperatures the nature of the 
solvents results in the formation of crystal seeds that grow the longer the solution is heated.59  
These nanoparticles have a high level of monodispersity and size control.  Maghemite crystals 
were obtained by thermal decomposition of iron pentacarbonyl at 100 °C in oleic acid and then 
increasing the temperature of the iron oleic complex to 300 °.60  Magnetite nanoparticles are 
created through the high-temperature reaction of iron(III) acetylacetonate with 1,2-
hexadecanediol in oleic acid and oleylamine.  These particles are hydrophobic and have 
diameters that can be tuned from 4 to 20 nm by modifying the ratio between oleic acid and 
oleylamine and the reaction temperature.28 
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Chapter 3 
3. Hybrid PET/MR Nanoparticle Synthesis 
To develop the synthetic process for the final hybrid PET/MRI nanoparticle, a number of steps 
were taken to synthesize similar nanoparticles that were useful in investigating the chemical 
process and SPION’s behavior in vivo.  Specifically, non-radioactive nanoparticles were 
produced to develop the chemistry of synthesis.  Then, 59Fe was incorporated, as a surrogate for 
52Fe, to develop the chemical process of incorporation.  Later, the 44.5 day half-life, allowed 
these 59Fe-SPIONs to be used for in vitro cell viability and uptake assays, and for in vivo 
biodistribution.  To enable the incorporation of manganese PET radionuclides, MnFe2O4 
nanoparticles were developed.  Finally, with the radionuclide and manganese incorporation 
chemistry established, the 52Mn-MIONs were synthesized.   
3.1. [59Fe]-SPION Synthesis 
The synthetic method of radionuclide incorporation was developed first by producing natural 
iron-oxide nanoparticle by previously established high temperature thermal decomposition 
synthesis.  Then a novel method for radio-intrinsic SPIONs was developed using 59Fe.  
3.1.1. Natural iron-oxide nanoparticle synthesis 
Synthesis of non-radioactive natural SPIONs was accomplished through high temperature 
thermal decomposition synthesis of maghemite crystals developed by Sun and Zeng. This 
process is detailed below: 
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(1) Combine iron(III) acetylacetonate [Fe(acac)3] (140 mg), (Z)-Octa-9-decenylamine 
[oleylamine] (395 μL), (9Z)-Octadec-9-enoic acid [Oleic acid] (380 μL), and 1,2-
hexadecanediol (517 mg), at a molar ratio of 1:3:3:5.  Dissolve the mixture in 10 ml 
benzyl ether for each millimole of Fe(acac)3. 
(2) Mix the reagents in a 50 mL three-neck flask under argon protection. 
(3) Heat the reaction solution to 200ºC in 30 minutes and maintain this temperature for two 
hours. 
(4) Increase the temperature to 300ºC in 30 minutes and maintain this temperature for one 
hour. 
(5) Cool the solution down to room temperature and add 50 mL of ethanol to precipitate the 
nanoparticles. 
(6) Centrifuge at 3100 g rcf for 5 minutes.  Remove the supernatant containing the non-
nanoparticle agents, suspend the nanoparticles in chloroform, and filter the nanoparticles 
solution by 0.22 μm nylon filter. 
This synthesis produces mono-crystalline nanoparticles coated with oleic acid and oleylamine 
and is useful for this project because the total reaction time is short enough to be appropriate for 
the incorporation short half-lived imaging radionuclides. 
Next, the reaction was scaled down as much as possible, so that smaller quantities of 
radionuclides can be used in future productions, while having a useful ratio of radioisotopes to 
stable isotopes.  The reaction starting reagent masses were reduced down to the point where 0.4 
millimoles (140 mg) of Fe(acac)3 is used while maintaining the same molar ratios of the other 
reagents. The use of smaller masses of reagents caused poor control of the reaction, which was 
reflected by fluctuation of reaction temperature and worse magnetization of nanoparticles. 
3.1.2. 59Fe incorporation 
The method to incorporate a radionuclide into the crystal structure of the SPION was developed 
using commercially purchased 59Fe that comes as an 59-iron(III) chloride in a aqueous solution 
of HCl. The first strategy used was to use between 5 and 300 μCi of 59-iron(III) chloride and 
mix it with the non-radioactive Fe(acac)3 before thermal decomposition reaction.  This yielded 
SPIONs with similar size as the non-radioactive synthesis.  The incorporation efficiently of the 
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59Fe was ~90%, with the unincorporated 59Fe being separated in step (6) of the synthesis into the 
supernatant. 
A second strategy was developed to achieve nanoparticles with higher 59Fe to natural iron ratios.  
This strategy begins with non-radioactive iron oxide cores and constructs an iron oxide shell 
around the core that incorporates the radionuclide. This is accomplished as detailed below: 
(1) Dry between 5 and 300 μCi of 59FeCl3 by heating the solution under vacuum to remove 
all water and HCl. 
(2) Add 20 mg Fe(acac)3, 517 mg 1,2-hexadecanediol, 150 μL oleylamine, 150 uL oleic acid, 
and 4 mL benzyl ether to the dried 59Fe in a 25 mL flask. 
(3) Add 12 mg (Fe) of the non-radioactive nanoparticles coated with oleic acid and 
oleylamine, suspended in chloroform to the 50 mL flask. Heat the reaction mixture under 
vacuum to remove the chloroform. 
(4) Mix this suspension and protect it from oxygen with argon gas flow.   
(5) Heat the reaction mixture in 30 minutes to 200ºC and keep at this temperature one hour. 
(6) Increase the reaction temperature in 30 minutes to 300ºC and keep this temperature for 1 
hour.   
This “thermal cycling” grows the iron oxide nanoparticles with a shell that incorporates 59Fe with 
an efficiency ranging from 80% to 95% and increases the nanostructure size observed in TEM 
(see Section 3.5).  Also, the mass of natural iron used in the final reaction is reduced, to achieve 
a higher 59Fe to natural iron ratio. 
3.2. [52Mn]-MION synthesis 
To achieve a hybrid PET/MRI nanoparticle, a positron emitting radionuclide must be utilized.  A 
viable candidate is 52Fe, which has positron emission (β+ = 55%) and a half-life (t1/2 = 8.275 h) 
long enough to be used in the thermal decomposition method previously developed in Section 
3.1.  This radionuclide was not utilized, because the small hospital based cyclotron available for 
this project is only commissioned for 12.9 MeV proton irradiation, and the proton energy needed 
to achieve the 55Mn(p,4n)52Fe is 54 MeV.61  Instead, manganese iron oxide nanoparticles 
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(MIONs) were synthesized, as previously described by Yang.62 Into these nanoparticles, we 
incorporated 52Mn, which is a positron emission radionuclide (β+ = 29.6%) with a moderate half-
life (t1/2 = 5.591 days).  Additionally, 52Mn can be produced through the available 12.9 MeV 
proton irradiation of natural chromium, as described in Section 3.2.3. 
3.2.1. Natural Manganese Iron Oxide Nanoparticle Synthesis 
Within the crystalline structure of the SPION, a number of divalent elements can be doped.  
Natural manganese was incorporated into the nanoparticle for the purpose of developing the 
chemical synthesis for the incorporation of positron emitting radionuclides of manganese.  The 
chemical method for manganese iron oxide nanoparticle is similar to the non-doped synthesis 
(Section 1.1.1), except one third of the iron atoms are replaced with manganese atoms.  This 
process was developed with natural manganese and is described below: 
(1) Combine 0.27 mmoles (94 mg) of Fe(acac)3, 0.13 mmole (47 mg) 
tris(acetylacetonato)manganese(III) [Mn(acac)3], 2 mmole (517 mg) 1,2-hexadecanediol, 
4 mL benzyl ether, 1.2 mmoles (395 μL) oleylamine, and 1.2 mmoles (380 uL) oleic acid 
in a 50 mL three-necked flask. 
(2) Mix the reagents under argon protection. 
(3) Heat the solution to 200ºC in 30 minutes and keep this temperature for two hours. 
(4) Increase the temperature to 300ºC in 30 minutes and keep this temperature for one hour. 
(5) Cool the solution down to room temperature and add 50 mL of ethanol to precipitate the 
nanoparticles. 
(6) Centrifuge at 3100 g rcf for 5 minutes.  Remove the supernatant containing the non-
nanoparticle agents and suspend the nanoparticles in chloroform. 
3.2.2. Core/shell synthesis of MIONs 
A core/shell structure synthesis incorporating natural manganese was developed to simulate the 
future incorporation of a PET manganese radionuclide.  This core/shell strategy was similar to 
the 59Fe incorporation strategy described in Section 1.1.2, but natural manganese(II) chloride 
(MnCl2) replaces the 59-Iron(II) chloride and Mn(acac)3 replaces one third of the Fe(acac)3: 
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(1) Dry .0285 mmoles (2 mg) of MnCl2 by heating the solution under vacuum. 
(2) Add the MnCl2 to 12 mg (Fe) of the manganese doped non-radioactive nanoparticles 
coated with oleic acid and oleylamine, suspended in chloroform, in a three-necked 
flask. Heat the reagents under vacuum to remove the chloroform.   
(3) Add 20 mg Fe(acac)3, 2 mmole (517 mg) 1,2-hexadecanediol, 150 uL oleylamine, 
150 uL oleic acid, and 4 mL benzyl ether to the manganese/iron-oxide cores in a 50 
mL flask.   
(4) Mix this suspension and protect it from oxygen with argon gas flow.   
(5) Heated over 30 minutes to 200ºC and hold at this temperature one hour. 
(6) Increase the reaction temperature over 30 minutes to 300ºC and hold this temperature 
for 1 hour. 
Similar to the 59Fe incorporation described in Section 1.1.2, this “thermal cycling” increases the 
nanostructure size observed in TEM (see Section 3.5.3). 
3.2.3. 52Mn cyclotron production 
The production of 52Mn was accomplished through 12.9 MeV proton irradiation of natural 
chromium to achieve the 52Cr(p,n)52Mn reaction.  A 99.995% purity natural chromium foil with 
0.25 mm thickness was purchased from Trace Sciences International Corporation.  This 
thickness was selected because it corresponds to the 12.9 – 7.8 MeV energy window, as shown 
in, Figure 6, which shows the energy a 12.9 MeV proton beam as it transverses chromium, based 
on chromium’s stopping power for protons.63 
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Figure 6: As the proton beam transverses the chromium target, it loses energy based on the stopping power of the 
chromium.  This figure depicts the kinetic energy remaining in a 12.9 MeV proton beam as it travels through 
chromium. 
Circular targets were formed from the foil with a 5.5 mm radius.  Each target weighed 120±11 
mg.  Foils were loaded into an iridium holder and secured with a steel clip, as shown in Figure 7. 
The initial cyclotron irradiation used an integral charge of 10 μAh.  Follow up irradiations used 
greater integral charges, up to 240 μAh.  Based on six separate irradiations, the yield was 108±9 
μCi/μAh.  This is 20% less that the theoretical yield predicted by the 52Cr(p,n)52Mn excitation 
function.64 This discrepancy is likely a result of a portion of the proton beam being blocked from 
the foil by the steel clip or missing the foil and being absorbed by the holder. 
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Figure 7: The target assembly used to support the chromium in the cyclotron beam.  The chromium foil target 
(center) is held to the iridium holder (outside) by a steel clip (middle) during the irradiation. 
Gamma energy spectrums of the irradiated foil were acquired with a high purity Ge gamma 
spectrometer (Ortec, Oak Ridge, TN), calibrated with a 152Eu source.  A representative gamma 
energy spectrum is shown in Figure 8.  The detector background was acquired separately and 
subtracted from the acquired spectrum.  52Mn is apparent from its multiple emissions and 54Mn is 
detected by its 834.91 keV gamma emission. The 54Mn (t1/2 = 312 d) is a byproduct of irradiating 
natural chromium, which contains 54Cr, allowing the 54Cr(p,n)54Mn reaction.  The 54Mn accounts 
for 0.5±0.1%, as determined through gamma energy spectroscopy.  Notably absent is a 320.1 
keV photon peak, which is characteristic of 51Cr, indicating that radionuclide has not been 
produced in detectable quantities.  
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Figure 8: The gamma energy spectrum of a natural chromium foil after 12.9 MeV proton irradiation.  The principle 
emissions of 52Mn and 54Mn are labeled.  Additionally, the 511 keV peak associated with β+ annihilation photons is 
labeled.  Also visible is the 346 keV peak of 52Mn. 
3.2.4. 52Mn radiochemical extraction 
In order to incorporate the small mass of 52Mn produced into our nanoparticles, the 52Mn needed 
to be purified and isolated from the bulk chromium and other metals.  Initially, an anion 
exchange method was developed for the chemical separation, but this method proved unsuitable 
for separating manganese from chromium.  Instead, a liquid-liquid extraction was developed to 
isolate the manganese radionuclides.  The extraction is depicted in Figure 9 and Figure 10.  This 
method was previously developed by Lahiri and is detailed below.65 
(1) Add the irradiated foil to 2 mL of 12 N HCl solution in a 25 mL glass flask. 
(2) Add 300 μL of 30% hydrogen peroxide solution and heat until the foil is totally dissolved 
and the solution is near dryness. 
(3) Add 2 mL of 12 N HCl solution and transfer the solution to a glass extraction tube. 
(4) Add 1 mL of 0.8 M trioctylamine (TOA) diluted in n-hexane.  Vortex the organic 
liquid/aqueous liquid mixture. 
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(5) Allow the aqueous phase to separate from the organic phase. The manganese 
radionuclides will transfer to the organic phase by forming a complex with TOA, while 
the chromium will stay in the aqueous solution.  Remove the organic phase. 
(6) Repeat steps 4 and 5 until ~95% of the activity has been extracted.  This requires 4-6 
repeats. 
(7) Re-extract the manganese radionuclides from the organic phase by adding 0.001 M 
NH4OH (ammonium hydroxide) aqueous solution to the organic phase and vortexing. 
(8) The activity will transfer to the re-extraction aqueous phase.  Repeat step 7 until ~95% of 
the activity is in the re-extraction aqueous solution.  This will take 2-3 repeats. 
(9) Heat the re-extraction solution until it is near dryness.  Re-dissolve the manganese 
radionuclides in 0.05 M HCl solution. 
 
Figure 9: Radiochemical extraction of 52Mn.  A) The chromium foil (gray) is loaded into an iridium holder (black) 
and irradiated with 12.9 MeV protons (red). B) 52Mn atoms (pink) are produced throughout the foil, which is 
unloaded from the holder.  C) The foil is then dissolved in 12 N hydrochloric acid and hydrogen peroxide while 
heating. The chromium (green) and manganese (pink) are disperse throughout the solution. D) The aqueous solution 
is mixed with the organic phase (yellow), trioctylamine diluted in n-hexane.  The aqueous phase then separates from 
the organic phase, with the majority of the manganese in the organic phase and the chromium in the aqueous phase. 
E) The organic phase (yellow) is collected for re-extraction of the 52Mn from the organic phase. F) The aqueous 
phase (green) still contains a portion of the 52Mn (pink) and can be further extracted. 
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Figure 10: Re-extraction of 52Mn from the organic phase produced from the extraction of manganese isotopes from 
the chromium isotopes. A) 52Mn (pink) is dissolved in trioctylamine diluted in n-hexane (yellow) as a result of the 
initial extraction. B) Ammonium hydroxide aqueous solution (blue) is added to the organic phase and vortexed.  The 
52Mn (pink) transfers to the aqueous phase. C) The aqueous phase (blue) containing the 52Mn (pink) is collected for 
future utilization in MION synthesis. D) The aqueous phase is further re-extracted to collect any remaining 52Mn. 
The entire extraction process was 91±6% efficient.  In order to obtain higher purity 52Mn, the 
extraction was repeated.  This further removed the bulk chromium from the final solution.  
Inductively coupled plasma mass spectrometry (ICP-MS) was utilized to quantify the specific 
activity and chromium contamination.  The initial specific activity was 108±4 μCi/ng of Mn with 
a 10.4±0.4 μCi/ng chromium contamination.  This indicates that the repeated extraction removed 
99.4% of the chromium.  The gamma energy spectrum of the extracted 52Mn solution was 
acquired and is shown in Figure 11.  The spectrum is similar to the un-extracted foil, because the 
only non-52Mn radionuclide that contributes to the spectrum is 54Mn, which cannot be chemically 
separated from all of the other manganese radionuclides. 
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Figure 11: The gamma energy spectrum of the separated manganese radionuclides is similar to that of the irradiated 
foil.  That is because the only major contributor to the spectrum aside from 52Mn is 54Mn, which cannot be 
chemically separated from the other manganese radionuclides. 
3.2.5. 52Mn incorporation 
To incorporate the 52Mn into the MIONs, initially a similar method to the 59Fe incorporation was 
utilized, with the 52Mn being incorporated into the shell of MION synthesis described in Section 
3.2.2.  The 52Mn solution was dried and added to the three-necked flask before the other reagents 
were added and then heated.  This approach produced [52Mn]-MIONs with a wide range of 
incorporation efficiencies, from 10-70%.  This synthetic strategy was not reproducible, therefore, 
the core/shell synthesis strategy, described in Section 3.2.2, was not utilized for further [52Mn]-
MION productions.  Instead, 52Mn incorporation was achieved by drying the 52Mn solution 
produced during the 52Mn radiochemical separation in a three-necked flask and then attending 
the reagents for a normal MION production as described in Section 3.2.1.  This process is 
depicted in Figure 12 and described below: 
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(1) Dry between 50 μCi and 14 mCi of 52MnCl2 by heating the solution in a 50 mL three-
necked flask under vacuum to remove all water and HCl. 
(2) Add 0.27 mmoles (94 mg) of Fe(acac)3, 0.13 mmole (47 mg) 
tris(acetylacetonato)manganese(III) [Mn(acac)3], 2 mmole (517 mg) 1,2-hexadecanediol, 
4 mL benzyl ether, 1.2 mmoles (395 μL) oleylamine, and 1.2 mmoles (380 μL) oleic acid 
in a 50 mL three-necked flask. 
(3) Mix the reagents under argon protection. 
(4) Heat the solution to 200ºC in 30 minutes and keep this temperature for two hours. 
(5) Increase the temperature to 300ºC in 30 minutes and keep this temperature for one hour. 
(6) Cool the solution down to room temperature and add 50 mL of ethanol to precipitate the 
nanoparticles. 
(7) Centrifuge at 3100 g rcf for 5 minutes.  Remove the supernatant containing the non-
nanoparticle agents, suspend the nanoparticles in chloroform, and filter the nanoparticles 
solution with a 0.22 μm nylon filter. 
 
Figure 12: Incorporation of 52Mn into the MION. A) 52Mn2+, natural Mn2+, and Fe3+/2+, are combined and heated to 
200ºC with oleic acid and oleylamine. B) Manganese iron oxide nanoparticle seeds form. C) The seeds grow into 
larger crystals incorporating 52Mn throughout and coated with oleic acid and oleylamine. 
3.3. Modification of Nanoparticles with Polymer Coating  
In order to make the hydrophobic oleic acid/oleylamine coated iron oxide nanoparticles water 
soluble, bio-compatible, and multi-functional, a multidentate poly-ethylene-glycol ligand was 
developed.  This ligand, shown in Figure 16, is composed of dopamine, poly-acrylic acid (PAA-
1800 MW), and poly-ethylene glycol (PEG-2000 MW).  The dopamine is not incorporated for 
targeting.  Instead, its two hydroxyl groups allow it to displace the oleic acid and oleylamine on 
the SPION and anchor the ligand to the surface of the nanoparticle through dipolar binding.  The 
repeating PAA unit acts as the molecular skeleton of the ligand, while the PEG-2000 confers 
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water solubility, biocompatibility, and favorable pharmacokinetics to the SPION. From previous 
studies, the multi-dentate ligands, have stronger interactions with nanoparticles for greater 
stability in vitro and in vivo.  The synthetic process for of PAA-Dopamine-PEG ligands is 
described below: 
(1) Dissolve 5.56 μmoles of PAA (100 mg) in 3 mL of dimethyl sulfoxide (DMSO). 
(2) Add 2 mmoles (319 mg) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 1.7 
mmlos (192 mg) N-Hydroxysuccinimide (NHS) while stirring.  Continue stirring for 4 
hours at room temperature. 
(3) Add 0.86 mmole (132 mg) dopamine hydrochloride and 0.7 mmole (1400 mg) N-
terminal amino group poly-ethylene-glycol (amino-PEG-2000) to the activated PAA 
solution and stir at room temperature for 16 hours. 
(4) Dialysis the solution with a 2,000 MW cutoff cassette to remove the unreacted molecules.  
Dry the product under vacuum and dissolve the ligands in deionized water. 
 
A number of other ligands were developed with different PEG chain lengths (550 and 2000 
MW).  SPIONs coated with these ligands suffered reduced water solubility.  Sodium dodecyl 
sulfate (SDS) was initially used during ligand exchange to increase these SPIONs’ water 
solubility and allow for relaxometry measurements, but it was later discovered that the dodecyl 
sulfate could not be separated from the nanoparticles after ligand exchange.  This reduced the 
nanoparticles’ biocompatibility and the use of dodecyl sulfate was discontinued.  Other ligands 
Figure 13: Multidentate poly-ethylene-glycol 
ligand for coating the SPIONs. It is composed 
of dopamine on the bottom left, which non-
covalently binds to the surface of the SPION, a 
repeating poly-acrylic acid (PAA-1800 MW) 
chain on the top, which is the back bone of the 
molecule, and a repeating poly-ethylene glycol 
(PEG-2000 MW) that provides 
biocompatibility and water solubility. 
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were developed that either partially or completely replaced the PEG chains with sulfobetaine to 
create zwitterionic (containing both positive and negative charge) ligands.  Without the use of 
dodecyl sulfate, these nanoparticles also suffered from reduced water solubility, in addition to 
possible aggregation and precipitation.   
3.3.1. Ligand exchange reaction 
The dopamine incorporate in the multidentate poly-ethylene-glycol ligand replaces the 
hydrophobic oleic acid/oleylamine coating on the iron oxide nanoparticles after a ligand 
exchange reaction.  After this reaction, the nanoparticles are separated from the oleic 
acid/oleylamine through centrifugation. This process is below:  
(1) Mix 6 nmoles of oleic acid/oleylamine coated SPIONs suspended in chloroform (2 mL) 
with an excess of multidentate poly-ethylene-glycol ligand (5 mmoles) dissolved in 
deionized water (0.5 mL). 
(2) Stir the mixture rigorously and heat to 60 °C for 30 minutes. 
(3) Precipitate the PAA-Dopamine-PEG coated SPIONs by adding hexane. 
(4) Centrifuge the SPIONs at 824 rcf for 5 minutes. 
(5) Collect and dry the pellet containing the SPIONs.  Then re-suspend them in deionized 
water. 
(6) Filter the suspension with a 0.22 μm nylon filter.   
(7) Then centrifuge again through a 30,000 MW cut off filter (Amicon filters) at 9,100 rcf for 
30 minutes to remove un-bound ligands and concentrate the SPION solution. 
3.3.2. Alternative coating strategy 
An alternative strategy for coating the superparamagnetic nanoparticles was developed from 
previously reported methods.66  The purpose of developing the alternative strategy was to 
directly compare the physical characteristics and in vitro uptake of an established coating with 
our novel coating approach.  The protocol for this strategy is detailed below: 
(1) 0.5 g of dopamine and 0.4 g of sodium nitrite was dissolved in 6 mL of DI water and 
cooled to 0 ºC. 
(2) Sulfuric acid (3.1 mmol in 2 mL of water) was added drop wise. 
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(3) This solution was stirred overnight, filtered with a 45 μm Millipore filter, and dried under 
vacuum to yield 270 μg nitrodopamine (NDA). This is a 43% reaction yield. 
(4) The chemical structure of NDA was confirmed by NMR. 
(5) A CHCl3 (3 mL) solution containing 7 mg of hydrophopic SPION was be mixed 
dropwise over 5 minutes while stirring with 2 mL of DMSO containing 10 mg of NDA. 
(6) After overnight reaction, the nanoparticles were separated by centrifuge (4180 rcf for 10 
minutes), washed with water twice, and filtered with a 30 kDa molecular weight cutoff 
filter. 
(7) CH3O-PEG2000MW-NHS was synthesized from (CH3O-PEG2000MW-NH2, as shown in 
Figure 14, by first reacting 1.0 g of CH3O-PEG2000MW-NH2 with 75 mg of succinic 
anhydride dissolved in 10 mL of chloroform.  4-Dimethylaminopyridine (6 mg) was 
included as a catalyst.  This product was then separated by silica gel chromatography, 
eluted with 4:1 chloroform to methanol solution.  The product (30 mg) was then reacted 
with 14.2 mg of (EDC) and 8.6 mg of (NHS) in 1 mL of DMSO.  This yielded 470 mg of 
CH3O-PEG2000MW-NH2, which was not further purified. 
(8) The NDA coated nanoparticles where then PEGylated as shown in Figure 15. CH3O-
PEG2000MW-NH2 (28 mg) was added to 2 mL DMSO containing 7 mg of NDA coated 
SPION under N2 atmosphere.  The mixture was bubbled with N2 for 30 minutes and 
allowed to react for 5 hours.  The SPIONs were then filtered with a 30 kDa molecular 
weight cutoff filter. 
 
Figure 14: Synthetic scheme to produce CH3O-PEG2000MW-NH2. This ligand is then used to coat the nanoparticle. 
 
Figure 15: Alternative coating strategy schematic. The oleylamine and oleic acid is first replaced with NDA on the 
surface of the nanoparticles.  Then, the CH3O-PEG2000MW-NH2 is added to react with the NDA and PEGylate the 
nanoparticles. 
3.3.3. Synthesis of coating ligand for bio-conjugation 
For further conjugation to targeting moieties, the multidentate poly-ethylene-glycol ligand was 
modified to incorporate PEG chains that included a terminal amine (NH2). These “amino-PEG” 
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chains were included in the ligand synthesis in a 2:1:1 ratio with the dopamine and unreactive 
PEG chain, as shown in Figure 16.  The number of reactive amine group in each polymer ligand 
will be ~6-7 based on the molecular design. Considering each SPION will be coated tens of to 
hundreds of ligands, the total number of reactive amine on each nanoparticles will be several 
hundreds, which is enough to conjugate large amount targeting molecules. This synthesis is 
similar to the method described in Section 3.3, with the exception that in step 3, only 700 mg 
diamino-PEG is used and 700 mg of amino-PEG-OCH3 is also included. 
 
Figure 16 Multidentateamino-PEG ligand for coating the SPIONs and bio-conjugation. It is composed of dopamine 
on the bottom left, which non-covalently binds to the surface of the SPION, a repeating poly-acrylic acid (PAA-
1800 MW) chain on the top, which is the back bone of the molecule, and repeating poly-ethylene glycol (PEG-2000 
MW), half of which include a terminal amine group for bio-conjugation reactions. 
3.3.4. Bio-conjugation reaction 
After the synthesis of amino-PEG, the SPIONs are coated as described in Section 3.3.1.  The 
resulting “amino-SPIONs” is then suspended in phosphate buffered saline (PBS) and conjugated 
with cRGD as described below.  A schematic of the reaction and the two strategies is shown in 
the figure below. 
(1) Amino-SPION (0.9 nmole) in PBS was transferred to a 10 mL vial. 
(2) An over-excess of bis(sulfosuccinimidyl) suberate (26 µg) was added under stirring and 
mixed for 30 minutes at room temperture.  The bis(sulfosuccinimidyl) suberate acts as a 
cross-linker between the SPION and the lysine-cRGD peptide. 
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(3) The reaction mixture was purified by Sephadex G25 column to remove unreacted 
Bis(sulfosuccinimidyl) suberate. 
(4) Amino-Cyclo-RGD (100 μg) was mixed with cross-linker activated SPION solution and 
stirred at room temperture for 4 hours.  
(5) The RGD-SPIONs were purified and concentrated by centrifuging through a 30,000 MW 
cut-off centrifuge filter at 9,000 rcf for 30 min. 
A second method for the RGD conjugation was developed using an alternative cross-linker, 
sulfo-SMCC. 
(1) Amino-SPION (0.9 nmole) in PBS was transferred to a 10 mL vial. 
(2) An over-excess of sulfo-SMCC (26 µg) was added to amino-SPION under stirring and 
reacted for 30 min at room temperture.  The sulfo-SMCC acts as a bifunctional cross-
linker between the SPION and the cysteine-cRGD peptide. 
(3) The reaction mixture was purified by Sephadex G25 column to remove unreacted sulfo-
SMCC. 
(4) Thiol-Cyclo-RGD (100 μg) was mixed with activated SPION solution and stirred at room 
temperture for 1 hour. T 
(5) The RGD-SPIONs were purified and concentrated by centrifuging through a 30,000 MW 
cut-off centrifuge filter at 9,000 rcf for 30 min. 
Figure 17 A) Schematic of the nanoparticle targeting with RGD peptide. B) The first strategy developed using 
the Bis(sulfosuccinimidyl) cross-linker. C) The second strategy developed using the sulfo-SMCC cross-linker.  
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3.4. SPION physical and magnetic characterization 
The physical and magnet properties of the SPIONs will influence their interaction with 
biological compartments and their usefulness as molecular imaging probes.  To characterize 
these properties, a number of methods were used.   
3.4.1. Transmission electron microscopy 
The size of the inorganic nano-crystal core was measured by imaging the nanoparticles through 
transmission electron microscopy (TEM) with a JEOL JEM-1230 Electron Microscope operating 
at an accelerating voltage of 120 KV.  The samples were prepared by spreading a dilute toluene 
solution of SPION onto carbon-coated copper grid (Formvar/Carbon 300 Mesh Cu).  These 
images were processed using ImageJ, an open source Java-written program developed by the 
National Institute of Health for image analysis.  The steps of this process are described below: 
(1) The scale of the image is defined in the software by matching a scale line to the scale bar 
in the TEM image. 
(2) The background of the image was removed by subtracting a Gaussian blur filter image 
with a radius much larger than the nano-particle size (usually 150 nm). 
(3) The image was thresholded to give high nano-particle contrast and sharp edges. 
(4) The ‘analyze particles’ tool was used to measure the area of the particles in the image.  
Usually around 300 nanoparticles are analyzed. 
(5) When the particles appear round in the image, the radius (r) of each particle is calculated 
from the area (A) as shown in equation 2:  
2  =  	/  
(6) An average radius is calculated and a histogram of the nanoparticles radius frequency is 
produced. 
3.4.2. Hydrodynamic size and zeta potential measurement 
The hydrodynamic size of the SPIONs differs from the size of the core, because the 
hydrodynamic size is measured while the nanoparticls are in suspension and it represents the 
whole size of the nanoparticle, including inorganic core and polymer layer.  The hydrodynamic 
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size of the nano-particles was measured through dynamic light scattering (DLS) using a Zeta 
Sizer Nano Series ZEN3600 (Malvern, USA).  In DLS, coherent monochromatic laser light (635 
nm) is diffracted by the nanoparticles.  The rate of change of the fluctuation of the diffraction 
pattern is related to the Brownian motion of the nanoparticle, which is related to the 
nanoparticles size. The zeta potential is the electrokinetic potential between the surface of 
nanoparticle coating and the dispersion medium.  This potential was also calculated with the Zeta 
Sizer Nano Series ZEN3600, by measuring the effect of an external electric field on the 
nanoparticle motion. 
3.4.3. Iron and manganese concentration measurement 
For the purposes of relaxometry and calculating the injected dose of nanoparticles it is necessary 
to measure the iron and manganese concentrations of each SPION suspensions.  This was 
accomplished through inductively coupled plasma (ICP) atomic emission spectroscopy with a 
Vista-MPX CCD Simultaneous ICP-OES (Varian).  In ICP, samples are excited and produce 
optical emission dependent on the atomic composition. The magnitude of the optical emission of 
an atom’s characteristic wavelength correlates to that atom’s concentration.  Standards of iron 
and manganese were used to find the characteristic wavelengths of iron at 238.2 nm, manganese 
at 257.6 nm and to make a calibration standard curve. Samples were digested for three days 
using a 7% nitric acid solution before ICP measurement. 
3.4.4. Relaxometry 
The strength of SPIONs as MR contrast agents is best evaluated by quantifying the increase in 
relaxation rate on the surrounding protons per unit concentration, or “specific relaxivity” (r2).  
This section will describe the method used to evaluate r2, while results from this method will be 
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given later in sections 3.5.1 through 3.5.5. Any data shown here is used as an example depicting 
the method. During relaxometry, the T2 perimeter is measured of a number of SPION doped 
vials.  T2 is the time at which the transverse magnetization is reduced to 37% (1/e) of its original 
value after excitation. The effect of the contrast agent on the water of each vial is best described 
using transverse relaxation rates (R2) rather than times (T2), which have an inverse relationship, 
as shown in equation 3. 
3 R2 = 1 / T2  
Relaxation rates are additive, so the relaxation rate observed in a vial (R’) is the sum of the 
water’s relaxation rate (R) and the relaxation induced by the SPIONs (RSpion). 
4 R’ = R + RSpion  
Within the range of concentrations useful for MRI imaging, the relaxation induced by the 
SPIONs is directly proportional to the concentration of the SPION (C) and the SPION’s specific 
relaxivity (r2), as depicted in equation 5. 
5 RSpion = r2C  
By combining equations 3, 4, and 5, it is possible to define the r2 of a SPION sample in terms of 
the T2 of a contrast free vial of water (T2water), the measured T2 of a contrast doped vial (T2vial), 
and the known SPION concentration (C) within that vial. 
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For each relaxometry measurement, a phantom was produced containing vials water suspended 
SPIONs at known concentrations of iron (as measured by ICP) and one contrast free vial.  A 
representative phantom and image are shown in Figure 18 for the purpose of describing the 
method, but results are shown in sections 3.5.1 through 3.5.5.   
 
Figure 18: The SPIONs are loaded into vials at known concentrations, including one control vial without any 
SPION added.  These vials are incorporated into a phantom that is imaged and the T2 value of each vial is 
calculated.  The decrease in T2 with respect to increasing SPION concentration yields the transverse relaxivity (R2) 
of the SPION sample. 
This phantom was imaged in the 7T BioSpec 70/30 small animal MRI scanner (Bruker), with a 
multiple-slice multiple-echo (MSME) sequence where the echoes are acquired at times (TE) 
ranging from 10 ms to 640 ms in 10 ms increments, and a repeat time (TR) of 12,000 ms.  This 
produces 64 images of one slice of the phantom at 64 different TEs, similar to the image in 
Figure 18.  The signal intensity from each voxel decreases with longer TEs at a rate defined by 
the transverse relaxivity (T2).  By plotting the signal intensity of a region of interest within each 
vial vs. echo time, as shown in Figure 19, the rate of signal loss can be fitted.  T2 is the time at 
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which the transverse magnetization—and with this imaging sequence, the signal, is reduced to 
37% (1/e) of its original value.  This value is calculated for a ROI within each vial. 
 
Figure 19 Plotting the signal of a vial’s ROI versus the echo time shows the transverse relaxation of the SPION 
suspension within each vial.  Higher concentrations of SPION (and higher vial numbers in this example) result in 
greater signal loss with increasing TE. 
Using the T2 of the SPION loaded vials (ms), the T2 of the non-SPION vial (ms), and the SPION 
concentrations (mM of Fe), the r2 of each vial was calculated using equation 6 (1/mM*s).  The 
average of all of the SPION loaded vials was used as the relaxivity value and the standard 
deviation of the measurements was used to evaluate the uncertainty. 
3.4.5. Gamma emission characterization and quantification 
The gamma emission spectrum was initially characterized for the 59Fe samples using a Perkin 
Elmer LKB Wallac 1282 compugamma CS universal gamma counter.  For quantification of 59Fe 
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using the gamma-counter, a program was implemented which windowed using channels 222 
through 236, corresponding to the 1099 keV and 1292 keV gamma emission.  The efficiency of 
the counter using this program was evaluated using equation 7 by comparing the emission from 
three 59Fe standards and their known nominal activities. 
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For 59Fe, the efficiency of the counter was 15.2 ± 0.2%.  
3.5. Nano-particle characterizations 
As an overview, the characteristics of TEM measured particle size, DLS measured 
hydrodynamic size, zeta potential, and relaxivity are shown for the 5 synthetic routes describes in 
Sections 3.1.1 through 3.2.2 and 3.2.5 are shown in Table 6.  All nanoparticles where coated 
with multidentate poly-ethylene-glycol ligands.  The natural SPIONs where coated molecular 
weight 550 PEG using the SDS ligand exchange described in 3.3.1, and thus does not have a 
valid zeta potential measurement.  All other nanoparticles in Table 6 are coated with molecular 
weight 2000 PEG and the ligand exchange was accomplished without the use of SDS. 
Table 6: Nanoparticle characteristics of different synthetic routs. 
Nanoparticle 
Metal(s) 
Nanoparticle 
structure 
TEM 
radius 
(nm) 
DLS 
radius 
(nm) 
Zeta 
potential 
(mV) 
Radionuclide 
used 
r2  
(s-1mM-1 of 
metal)
 
Fe Core 4.3 ± 1.3 25 ± 5 NA None 72 ± 10 
Fe Core/Shell 5.0 ± 1.5 17 ± 6 -46 ± 5 59Fe (130 μCi) 97 ± 3 
Fe, Mn Core 3.3 ± 1.0 15 ± 5 -20 ± 6 None 90 ± 1 
Fe, Mn Core/Shell 4.4 ± 1.6 18 ± 4 -16 ± 4 None 234 ± 8 
Fe, Mn Core 4.0 ± 1.0 17 ± 5 -42 ± 9  52Mn 220 ± 40 
Fe, Mn Core/cRGD 4.0 ± 1.0 34 ± 14 -27 ± 17  52Mn 200 ± 20 
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The relaxivity of the nanoparticles varied considerably between different production batches.  
This is possible due to difficulty controlling the aspects of reaction environment, such as 
temperature.  Unlike organic synthesis, the synthesis of nanoparticles is not 100% reproducible 
because the final product is a mixture of different size/composition particles. The relaxivity of 
samples remained stable up to one month, as shown in Table 7.  
Table 7: Relaxometry results of a single MION sample over one month.  Nanoparticles where coated with 
molecular weight 2000 PEG. 
Date of relaxometry Nanoparticle 
Metal(s) 
Nanoparticle 
structure 
r2 (1/s*mM of 
metal) 
5/11/2012 Fe, Mn Core 140 ± 8 
5/18/2012 Fe, Mn Core 134 ± 10 
5/25/2012 Fe, Mn Core 136 ± 6 
6/12/2012 Fe, Mn Core 130 ± 10 
3.5.1. Natural SPION 
The first step of the hybrid PET/MRI nanoparticle synthetic development was to create a non-
radioactive SPION core and to coat the SPION with a multidentate poly-ethylene-glycol ligand 
to make the nanoparticle water-soluble and biocompatible. Transmission electron microscopy 
(TEM) images of these SPIONs were then produced and analyzed as described in Section 3.4.1.  
A representative TEM image and its analysis are shown in Figure 20. The SPION radius 
measured from the TEM image, which is characteristic of the nanoparticles’ inorganic core, was 
4.3 ± 1.3 nm.  The SPION hydrodynamic radius was 25 ± 5 nm, as shown in Figure 21 (see 
Section 3.4.2 for method). The zeta-potential measurement is not available for these 
nanoparticles, because the use of SDS during the ligand exchange (as explained in Section 3.3.1) 
made the measurements invalid.  After the iron concentration of the SPION solution was 
measured using ICP (see Section 3.4.3), the relaxivity of the SPIONs was measured and 
calculated to be 72 ± 10 (s*mM of iron)-1. 
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Figure 20: Representative TEM image and histogram of natural SPIONs coated with oleic acid and oleylamine.  
Samples were prepared by spreading a dilute toluene solution of SPION onto carbon-coated copper grid. The size 
measured of each particle is characteristic of the size of the inorganic iron oxide core. 
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Figure 21: Hydrodynamic radius distribution of natural multidentate poly- ethylene-glycol coated SPIONs as 
measured through DLS.  The left peak is SPION size and the right peak likely represents a small fraction of 
nanoparticle aggregation. 
3.5.2. 59Fe SPION 
The synthesis of 59Fe-SPIONs was accomplished with the synthetic method described in Section 
3.1.  TEM images of these 59Fe-SPIONs were then produced and analyzed as described in 
Section 3.4.1.  A representative TEM image and its analysis are shown in Figure 22. The SPION 
radius measured from the TEM image, which is characteristic of the nanoparticles’ inorganic 
core, was 5.0 ± 1.5 nm.  The 59Fe-SPION hydrodynamic radius was 17 ± 6 nm and the zeta-
potential was -46 ± 5 mV, as shown in Figure 23 (see Section 3.4.2 for method).  After the iron 
concentration of the SPIONs was measured using ICP (see Section 3.4.3), the relaxivity of the 
SPIONs was measured to be 97 ± 3 (s*mM of iron)-1.  The 59Fe-SPIONs had an activity to iron 
mass ratio of 32 ± 2 μCi/mg of Fe. 
Successful incorporation of 59Fe was verified by separating the nanoparticles at 3100 rcf from 
unreacted iron and by comparing the TEM size of the core to the core/shell structure.  The 
nanoparticle radius increased between 0.5 – 2 nm from the addition of the 59Fe doped shell. 
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Figure 22: TEM image and histogram of 59Fe-SPIONs coated with oleic acid and oleylamine.  Samples were 
prepared by spreading a dilute toluene solution of SPION onto carbon-coated copper grid. The size measured of 
each particle is characteristic of the size of the inorganic iron oxide core.  
0
20
40
60
80
100
120
140
160
180
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10
#
 o
f 
p
a
rt
ic
le
s
radius (nm)
59Fe-SPION size distrubution
n = 1018 particles
radiusmean = 5.0 ± 1.5
 53 
 
 
 
Figure 23: Hydrodynamic radius (top) and zeta potential (bottom) of 59Fe-SPION. 
3.5.3. Natural MION 
The synthesis of natural MIONs was accomplished with the synthetic method described in 
Section 3.2.1.  TEM images of these MIONs were then produced and analyzed as described in 
Section 3.4.1.  A TEM image and its analysis are shown in Figure 24. The MION radius 
measured from the TEM image, which is characteristic of the nanoparticles’ inorganic core, was 
3.3 ± 1.0 nm.  The MION hydrodynamic radius was 15 ± 5 nm and the zeta-potential was -20 ± 6 
mV, as shown in Figure 25 (see Section 3.4.2 for method).  After the iron and manganese 
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concentration of the MIONs was measured using ICP (see Section 3.4.3), the relaxivity of the 
MIONs was measured to be 97 ± 3 (s*mM of metal)-1. 
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Figure 24: TEM image and histogram of MIONs coated with oleic acid and oleylamine.  Samples were prepared by 
spreading a dilute toluene solution of SPION onto carbon-coated copper grid. The size measured of each particle is 
characteristic of the size of the inorganic iron oxide core.  The clumping of the nanoparticles seen in the TEM image 
may be a result of the evaporation pattern of the toluene solution. 
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Figure 25: Hydrodynamic radius (top) and zeta potential (bottom) of MION. 
3.5.4. MION core/shell 
The synthesis of natural MIONs with a core/shell structure was accomplished with the synthetic 
method described in Section 3.2.2.  TEM images of these MIONs were then produced and 
analyzed as described in Section 3.4.1.  A TEM image and its analysis are shown in Figure 18. 
The MION radius measured from the TEM image, which is characteristic of the nanoparticles’ 
inorganic core, was 4.4 ± 1.6 nm.  The MION hydrodynamic radius was 18 ± 4 nm and the zeta-
potential was -16 ± 4mV, as shown in Figure 27 (see Section 3.4.2 for method).  To allow for 
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direct comparison, this data depicts the same nanoparticle cores as shown in Section 3.5.3, but 
after the addition of the shell layer. After the iron and manganese concentration of the MIONs 
was measured using ICP (see Section 3.4.3), the relaxivity of the MIONs was measured to be 
234 ± 8 (s*mM of metal)-1. 
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Figure 26: TEM image and histogram of MIONs with a core/shell structure coated with oleic acid and oleylamine.  
Samples were prepared by spreading a dilute toluene solution of SPION onto carbon-coated copper grid. The size 
measured of each particle is characteristic of the size of the inorganic iron oxide core.  
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Figure 27 Hydrodynamic radius (top) and zeta potential (bottom) of MIONs with a core/shell structure.  The second 
smaller peak in the DLS figure is possibly caused by minor sample contamination. 
3.5.5. [52Mn]-MION 
The synthesis of 52Mn-MIONs was accomplished with the synthetic method described in Section 
3.2.5.  TEM images of these 52Mn-MIONs were then produced and analyzed as described in 
Section 3.4.1.  A representative TEM image and its analysis are shown in Figure 30. The MION 
radius measured from the TEM image, which is characteristic of the nanoparticles’ inorganic 
core, was 4.0 ± 1.0 nm.  The 52Mn-MIONs hydrodynamic radius was measured twice.  Once for 
the untargeted nanoparticles and once for the cRGD conjugated MIONs.  For the untargeted 
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MIONs, the hydrodynamic radius was 17 ± 5 nm and the zeta-potential was -17 ± 5 mV, (see 
Section 3.4.2 for method), as shown in Figure 28. For the cRGD conjugated MIONS, the 
hydrodynamic radius was 34 ± 14 nm and the zeta-potential was -27 ± 17, as shown in Figure 29.  
The increase in hydrodynamic size is likely a result of the addition of cRGD peptide to the nano-
structure and the greater unraveling of the multi-dentine PEG ligands.  After the iron 
concentration of the MIONs was measured using ICP (see Section 3.4.3), the relaxivity of the 
cRGD conjugated MIONs and the untargeted MIONs was measured to be 220 ± 40 (s*mM of 
iron)-1 and 200 ± 20 (s*mM of iron)-1 respectively.  These measurements represent the cRGD 
targeted and the untargeted MIONs used in the animal experiments described in chapter 5.  The 
52Mn-MIONs had a activity to mass of iron ratio of 1.47 ± .06 μCi/mg of Fe. 
Successful incorporation of 52Mn was verified by separating the nanoparticles at 3100 rcf to 
isolate the nanoparticles from unreacted iron and manganese. 
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Figure 28: Hydrodynamic radius (top) and zeta potential (bottom) of untargeted 52Mn-MIONs. 
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Figure 29: Hydrodynamic radius (top) and zeta potential (bottom) of 52Mn-MION-cRGDs. 
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Figure 30: TEM image and histogram of 52Mn-MIONs coated with oleic acid and oleylamine.  Samples were 
prepared by spreading a dilute toluene solution of SPION onto carbon-coated copper grid. The size measured of 
each particle is characteristic of the size of the inorganic manganese iron oxide core. 
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Chapter 4 
4.  [59Fe]-SPION Evaluation 
To evaluate the potential of this nanoparticle for targeted molecular imaging, the non-targeted 
SPION’s in vivo behavior was evaluated.  Specifically, the [59Fe]-SPIONs were utilized in 
imaging and biodistribution studies with non-tumor bearing mice.  Injected mice were MR 
imaged and the MR results were compared with the biodistribution results.  Finally, signal 
contrast mapping was demonstrated using the imaging data obtained before and after [59Fe]-
SPION injection imaging results. 
4.1. [59Fe]-SPION Biodistribution 
In order to evaluate the in vivo pharmacokinetics of the non-targeted nanoparticles, a 
biodistribution study was conducted using 59Fe-SPIONs.  All animal experiments were approved 
and performed according to the policies and guidelines of the Institutional Animal Care and Use 
Committee (IACUC) at Virginia Commonwealth University.  Adult male and female nude mice 
(n=15) were injected through the tail-vein with 26 ± 1 ug Fe and 840 ± 30 nCi of 59Fe-SPION.  
Doses were drawn, weighed, and then diluted with saline to 200 μL.  
The mice (3) were sacrificed at each of five time points ranging from 1 to 144 hours post 
injection.  Tissues were harvested, weighed, and the gamma-emission was measured.   
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The percent injected dose per gram (%ID/g) of each tissue was calculated from the decay 
corrected activity of the tissue (tissue activity), the activity injected, and the mass of the tissue, 
using equation 8.  The injected activity was calculated by measuring the mass of the empty 
syringe and the full syringe.  The difference represended the mass of nanoparticle solution in the 
syringe (g), and this was related to the activity (CPM) by measuring the activity of a known 
standard of SPION solution (CPM/g).  The residual activity in the syringe after injection was 
measured (CPM) and subtracted from the activity in the syringe to give the injected activity 
(CPM).67 
A similar procedure was used to characterize the biodistribution of 59FeCl3, as a non-SPION 
control at 24 hours and 144 hours after injection.  An aqueous solution (1 μL) of 59FeCl3 in 
hydrochloric acid was diluted into 600 μL of deionized water, and neutralized to pH 3.5 with 
.00023 M sodium hydroxide.  Doses were drawn to 40 μL (0.23±.3 μCi) and then further diluted 
to 200 μL with saline solution before injection.  The %ID/g of each tissue was calculated as 
described above. 
4.2. MR imaging of 59Fe-SPION 
In order to establish the usefulness of the iron oxide nanoparticles as MR contrast agents, each 
mouse of the 59Fe-SPION biodistribution study was MR imaged before injection and before 
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sacrifice using the 7T BioSpec 70/30 small animal MRI scanner (Bruker, Billerica, MA).  A Fast 
Imaging with Steady State Precession (FISP) sequence was used with a repeat time (TR) of 9.4 
ms and echo time (TE) of 4.7 ms and number of scans averaged (NSA) of 4.  A flip angle (FA) 
of 35º was used to achieve T2*/T1 weighted images.  Smaller flip angles were used to achieve 
proton density weighted images and larger flip angles resulted in images with unacceptably low 
signals. The short TR (9.4 ms) allowed for a 384×128×128 matrix acquisition with isotropic 274 
micron voxels (FOV = 10.5×3.5×3.5 cm).  The isotropic acquisition of specifically developed to 
allow for future comparison with isotropic PET data.  Attenuator and receiver gain values were 
recorded from the pre-injection imaging and reused for the pre-sacrifice imaging. 
The un-gated acquisition time was 614 s.  A bellows was placed under the mouse and a Control / 
Gating Module (SA Instruments) was used to acquire the mouse’s respiratory cycle.  The MR 
sequence was actively gated to avoid acquisition during inhalation and exhalation.  This gating 
increased the acquisition time to ~13 minutes.  The mice were anesthetized under 2% isoflurane 
flow during imaging.  The images were exported in Digital Imaging and Communications in 
Medicine (DICOM) format for processing and analysis using the 3DSlicer software package.68 
Regions of interest (ROIs) were drawn on the brain, kidneys, and liver of each mouse before and 
after injection to quantify the contrast caused by the 59Fe-SPION injection at different times.  
The contrast was compared with the 59Fe accumulation from the biodistribution study.  Then a 
phantom containing known concentrations of SPION iron was imaged using the same MR 
sequence that was used for the in vivo imaging to produce a standard curve of SPION iron 
concentration versus MR contrast in water.  By linearly interpolating between the points on the 
standard curve, the SPION iron concentration of each ROI was evaluated.  These concentration 
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values from the MRI data were compared to concentration values calculated from the 
biodistribution %ID/g values, as shown in equation 9. 
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4.3. Signal contrast mapping 
The SPIONs effectively reduced the MR signal from a number of tissues.  To spatially 
characterize this effect, signal contrast maps were created from the pre-injection and pre-
sacrifice images.  The pre-sacrifice images were deformed and co-registered to the pre-imaging 
images using the basis spline algorithm available in the 3DSlicer software package 
(BRAINSFit).  The quality of the co-registration was only evaluated visually.  The percent signal 
contrast (%SC) of each voxel was then calculated from the pre-injection signal (Sinjection) and the 
pre-sacrifice signal (Ssacrifice) using equation 10. 
10 %% =
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Voxels that resulted in a negative %SC, or “signal gain,” where thresholded to a %SC value of 
zero, as the signal gain is not accurately attributed to of the SPION injection.  Initially, the signal 
contrast mapping was developed for analytical comparison with PET data, but due to the 
difficulty of deformably co-registering PET/CT to MRI datasets, ROI analysis was utilized 
instead. 
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4.4. [59Fe]-SPION in vivo evaluation results 
4.4.1. Biodistribution 
The %ID/g values of the 59Fe-SPIONs in blood and other major organs at different times after 
injection is given in Table 8 and shown in Figure 31.  These values differed from the 59FeCl3 
biodistribution given in Table 9 and shown in Figure 32, indicating that the SPION nano-
structure was affecting the 59Fe pharmacokinetics.  Both 59Fe-SPIONs and 59FeCl3 exhibit 
accumulation in the liver and spleen. The accumulation of 59Fe-SPION in the spleen was 
significantly less than the accumulation of 59FeCl3 at both 24 hours (p =  0.012) and 144 hours (p 
= 0.019).  At 24 hours, the accumulation of 59Fe-SPION in the liver (39±3 %ID/g) was not 
significantly less than 59FeCl3 (46±8 %ID/g) accumulation (p = 0.23), but at 144 hours there was 
significantly less 59Fe-SPION accumulation in the liver (31±2 %ID/g) than 59FeCl3 (50±10) 
accumulation (p = 0.041).   
Table 8: Biodistribution of intravenously injected 59Fe-SPIONs in nude mice (n=3 per time point).  Data are 
presented as %ID/g (mean±stdv) values determined through gamma counting. Nude mice (n=3 per time point) were 
injected through the tail vein with 59Fe-SPIONs (0.84±0.03 μCi; 200 μL; 26±1 μg of Fe).  Tissues were collected, 
weighted, and the gamma emission was measured to calculate the %ID/g. 
Organs 1 Hour 4 Hour 24 Hours 72 Hours 144 Hours 
Blood 3.9±0.7 1.4±0.3 2.8±0.2 4±0.4 5.5±0.7 
Heart 1.2±0.2 0.48±0.07 0.51±0.02 0.8±0.3 0.9±0.2 
Lungs 1.9±0.5 0.94±0.04 1.2±0.2 1.3±0.4 1.8±0.2 
Liver 46±7 30±7 39±3 33±5 31±2 
Spleen 16±6 19±2 17.5±0.9 14±5 15.2±0.3 
Stomach 0.4±0.3 0.13±0.04 0.25±0.05 0.2±0.2 0.26±0.1 
Intestines 0.7±0.2 0.9±0.1 1.4±0.1 1.3±0.4 0.8±0.1 
Kidneys 1.4±0.2 0.7±0.1 0.99±0.1 0.7±0.2 1.4±0.2 
Skin 0.9±0.4 0.5±0.2 0.7±0.1 0.9±0.2 0.81±0.03 
Muscle 0.9±0.6 0.3±0.3 0.19±0.07 0.3±0.3 0.36±0.07 
Skull 2.1±0.9 1.8±0.3 1.5±0.4 2.1±0.4 4±1 
Brain 0.14±0.05 0.1±0.1 0.12±0.03 0.12±0.01 0.28±0.08 
Femur 5.4±0.5 4.9±0.9  7±2 5.3±0.9 4±1 
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Figure 31: Biodistribution (%ID/g) at various time points post intravenous administration.  Nude mice (n=3 per 
time point) were injected through the tail vein with 59Fe-SPIONs (0.84±0.03 μCi; 200 μL; 26±1 μg of Fe).  Tissues 
were collected, weighted, and the gamma emission was measured to calculate the %ID/g. 
Table 9: Biodistribution of tail-vein injected 59FeCl3 (0.23±.3 μCi) in nude mice (n=3 per time point).  Data are 
presented as %ID/g (mean±stdv) values determined through gamma counting. Tissues were collected, weighted, and 
the gamma emission was measured to calculate the %ID/g. 
Organ 24 Hours 144 Hours 
Blood 14±2 28±4 
Heart 3±0.3 4.1±0.5 
Lungs 7±1 11±3 
Liver 46±8 50±10 
Spleen 41±5 48±9 
Stomach 4±2 1.1±0.5 
Intestines 6±1 2.1±0.8 
Kidneys 5.8±0.6 6.1±0.7 
Skin 2.2±0.4 3.4±1 
Muscle 0.9±0.1 1±0.2 
Skull 5±2 10±4 
Brain 0.5±0.2 1.13±0.1 
Femur 21±6 10±2 
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Figure 32: Biodistribution (%ID/g) at various time points post tail-vein administration (0.23±.03 μCi; 200 μL) of 
59FeCl3. Tissues were collected, weighted, and the gamma emission was measured to calculate the %ID/g. 
4.4.2. MR imaging 
Representative MR images of the 59Fe-SPION injected mice are shown before and at 1 hour post 
injection in Figure 33, at 4 hours post injection in Figure 34, at 24 hours post injection in Figure 
35, at 72 hours post injection in Figure 36, and at 144 hours post injection in Figure 37.  High 
contrast was observed in the liver, while medium contrast was observed in the kidneys, and little 
or no contrast was observed in the brain.  ROIs were drawn on these three larger tissues, and the 
contrast gained by the SPION injection was quantified and compared to the 59Fe-SPION 
biodistribution data in Figure 38.  A standard curve of contrast (% Signal) versus 59Fe-SPION 
iron concentration (mg/L) was produce and is shown in Figure 39.  Concentrations between the 
known values where linearly interpolated, as shown by the connecting line segments.  The 
SPION iron concentration values calculated from the MRI data and the biodistribution study are 
shown in Figure 40.  SPION iron concentrations calculated from MRI ROI data were greater 
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than values calculated from the biodistribution study by a mean factor of 62±38 in the liver, a 
factor of 3.2±1.8 in the kidneys, and 0.55±0.25 in the brain. 
 
Figure 33: Sagittal MR images of 59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse 
before (left) and 1 hour (right) after injection.  The mouse was imaged with a Fast Imaging with Steady State 
Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans 
averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows 
indicate the brain, the red arrows indicate the liver, and the yellows arrows indicate the bladder. 
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Figure 34: Sagittal MR images of 59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse 
before (left) and 4 hours (right) after injection.  The mouse was imaged with a Fast Imaging with Steady State 
Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans 
averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows 
indicate the brain, the red arrows indicate the liver, and the yellows arrows indicate the bladder.   
 
Figure 35 Sagittal MR images of 59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse before 
(left) and 24 hours (right) after injection.  The mouse was imaged with a Fast Imaging with Steady State Precession 
(FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans averaged 
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(NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows indicate the 
brain, the red arrows indicate the liver, and the yellows arrows indicate the bladder.  averaged (NSA) of 4.  A flip 
angle (FA) of 35º was used to achieve T2*/T1 weighted images.  
 
Figure 36: Sagittal MR images of 59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse 
before (left) and 72 hours (right) after injection.  The mouse was imaged with a Fast Imaging with Steady State 
Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans 
averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows 
indicate the brain, the red arrows indicate the liver, and the yellows arrows indicate the bladder.    
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Figure 37: Sagittal MR images of 59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse 
before (left) and 144 hours (right) after injection.  The mouse was imaged with a Fast Imaging with Steady State 
Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans 
averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows 
indicate the brain, the red arrows indicate the liver, and the yellows arrows indicate the bladder.   
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Figure 38: The MR contrast caused by the SPION injection as measured by ROI analysis of various tissues (top) 
and the %ID of those tissues from the biodistribution (below) for comparison.  Mice were tail-vein injected with 
59Fe-SPION (26 ± 1 ug Fe and 840 ± 30 nCi) and imaged and sacrificed at different time points. 
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Figure 39: The standard curve of the % signal contrast versus 59Fe-SPION iron concentration.  The connecting line 
segments represent the linear interpolation used to evaluate values between the known concentrations.  The phantom 
was imaged with a Fast Imaging with Steady State Precession (FISP) sequence with a repeat time (TR) of 9.4 ms 
and echo time (TE) of 4.7 ms and number of scans averaged (NSA) of 4.  A flip angle (FA) of 35º was used to 
achieve T2*/T1 weighted images.   
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40
%
 S
ig
n
a
l
SPION concentration (mg/L of Fe)
59Fe-SPION Standard Curve
 77 
 
 
Figure 40: SPION iron concentration values are calculated from MRI ROI data and 59Fe-SPION biodistribution 
%ID/g values for the liver (top), kidney (middle), and brain (bottom). Mice were tail-vein injected with 59Fe-SPION 
(26 ± 1 ug Fe and 840 ± 30 nCi) and imaged and sacrificed at different time points. 
The large discrepancy in the liver between the %ID/g values and the MR standard curve values 
may be a result of the fact that the % contrast induced by the nanoparticles plateaus at higher 
concentrations, and the liver has high uptake.  Additionally, the % contrast depends on the 
interaction between the SPIONs and the surrounding hydrogen nuclei.  This interaction can be 
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affected by a number of factors, including the cellular and sub-cellular localization of the 
SPIONs, the temperature of the tissue, and the surrounding of the nanoparticles with proteins.  
These variables and the results shown here indicate the difficulties measuring probe 
concentration from MR data.  This challenge shows a potential strength of a hybrid PET/MRI 
nanoparticle, where probe concentration information is derived from PET data, while MR data is 
used for spatial information.  
4.4.3. Signal contrast mapping 
A representative signal contrast map is shown in Figure 41. The left image shows the central 
sagittal slice of the mouse before 59Fe-SPION injection.  The center image shows the mouse 24 
hours post-injection and the right image is the % contrast map produced from the post and pre-
injection images.  The central slice shows contrast in the liver and back bones. Other slices show 
contrast in the kidneys.  No contrast is seen in the intestines, stomach, or brain. 
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Figure 41: 59Fe-SPIONs (26 ± 1 ug Fe and 840 ± 30 nCi) tail-vein injected nude mouse before (left) and 24 hours 
(middle) after injection.  The mouse was imaged with a Fast Imaging with Steady State Precession (FISP) sequence 
with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of scans averaged (NSA) of 4.  A flip 
angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue arrows indicate the brain, the red arrows 
indicate the liver, and the yellows arrows indicate the bladder.  The right image shows the % contrast map, 
calculated by the difference of the before and after (deformably co-registered) images, divided by the before 
injection image. 
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Chapter 5 
5. [52Mn]-MION-cRGD Evaluation 
To demonstrate the use of hybrid PET/MRI nanoparticle in targeted molecular imaging, the 
[52Mn]-MION-cRGDs were utilized to image nude mice bearing U87MG xenograft tumors.  As 
a precursor to this study, the PET characteristics of spatial resolution, sensitivity, and count rate 
linearity, for 52Mn and two other imaging radionuclides were characterized in a small animal 
PET/SPECT/CT scanner (Inveon, Erlangen, Germany).  For all PET studies, signal was acquired 
within a 350 - 650 keV energy window, and images were reconstructed with the 3D-
OSEM+MAP reconstruction algorithm (0.78 mm voxel size), except for images used for spatial 
resolution measurements, which were reconstructed with the filtered back projection algorithm 
(0.39 mm voxel size). Additionally, the αVβ3 integrin expression of the U87MG cells before and 
after implantation was characterized using fluorescent anti-body staining and flow cytometry. 
5.1. PET characterization of imaging radionuclides 
The physical decay characteristics of every imaging radionuclide affect the image quality of that 
radionuclide.  Specifically, the positron decay energy will affect the image spatial resolution, 
while additional gamma rays produced by non-pure positron emitting radionuclides may change 
sensitivity and count rate linearity.  In order to assess these effects, the spatial resolution, 
sensitivity, and count rate linearity of 52Mn, 18F and 89Zr were measured with a small animal 
PET/SPECT/CT scanner.  The methods used to assess each characteristic are described in the 
following three sections. 
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5.1.1. Spatial Resolution 
The spatial resolution of each radionuclide was assessed by loading a thin tube, with inner 
diameter of 0.39 mm, with 5-27 μCi of the imaging radionuclide.  This tube was placed within an 
acrylic glass phantom shown in Figure 42.  The phantom has four bores, which act as four 
positions of the radionuclide during scanning.  The central bore was placed to cover the scanner 
isocenter.  The phantom was imaged with the PET scanner long enough to acquire 100 million 
counts. For spatial resolution measurements, images were reconstruction using a filtered back 
projection algorithm and a 0.78 mm voxel size.  The full width at half maximum (FWHM) of the 
signal from each position was measured using AMIDE, a medical imaging data examining 
software.69  This measurement was repeated ten times for each position and the standard 
deviation of the measurement was used to assess uncertainty. 
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Figure 42: The acrylic glass cube functions as a phantom, holding the radionuclide loaded tube at four positions 
within the scanner.  The cube is 5 cm in each dimension and has a density of 1.13 ± 0.05 g/cm3. The bores within the 
block, shown in the top right, are displaced by 0 mm × 0 mm, 0 mm × 10 mm, 15 mm × 15 mm, and 20 mm × 20 
mm.  The tube goes through be bores, as shown (bottom). 
5.1.2. Sensitivity Measurement 
The assessment of sensitivity (counts/decay) was accomplished by loading a 16.8 mL vial with 
known activities of the radionuclide.  Before scanning, the activity of each vial was measured 
with a re-entrant ionization chamber or “dose calibrator” (Capintec, Ramsey, NJ, USA).  The 
ionization chamber was calibrated with a known activity 52Mn, 18F and 89Zr.  These known 
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activities were measured with the high purity Ge gamma spectrometer, described in Section 
3.2.3. The 16.8 mL vial phantom, shown in Figure 43, was then imaged for 5 minutes with the 
small animal PET scanner. The phantom approximated the size of the mice to be used later for 
the imagine study, and were positioned within the scanner to approximate the mice’s positions. 
The number of true counts was then compared to the known activity and the sensitivity was 
calculated.  This measurement was done with ten known activities for 52Mn and 89Zr, and 34 
known activities for 18F.  The activities used covered the range from 5 μCi to 500 μCi, which 
included the range of activities that would be used in the animal imaging experiments.  The 
standard deviation of the measurements was calculated and used to assess the measurement’s 
uncertainty.  The scanner efficiency (counts/positron decay) was also calculated, by dividing the 
sensitivity by the positron yield of each radionuclide. 
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Figure 43: Radionuclide filled vial, containing 16.8 mL of water.  This vial serves as a phantom for sensitivity and 
count rate linearity measurements for 52Mn, 18F, and 89Zr.  
5.1.3. Count Rate Linearity 
In order to measure the count rate linearity of 52Mn, 18F and 89Zr, the same phantoms described 
in Section 5.1.2 were utilized.  Known activities ranging from >500 μCi to <5 μCi were used 
because this covered the range of activities that would be used in the mouse imaging study.  Each 
sample was PET imaged for 5 minutes and the number of true counts was plotted as a function of 
the known activity.  This plot was then fitted with a linear regression and the R2 value was 
calculated to evaluate the linearity of the response. 
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5.1.4. 18F Characterization 
The PET imaging characteristics of 18F, a widely used PET radionuclide, were assessed.  18F has 
110 minute half-life, a positron yield of 96.7%, and mean positron energy of 250 keV. The 
spatial resolution of 18F measured at the four positions is shown in Table 10.   
Table 10: The full width at half maximum of the reconstructed 18F spatial resolution phantom image at different 
offsets from the PET scanner isocenter. 
Position Offset Full width at half maximum (mm) 
0 mm × 0 mm 2.01 ± 0.03 
0 mm × 10 mm 2.03 ± 0.05 
15 mm × 15 mm 2.09 ± 0.02 
20 mm × 20 mm 2.32 ± 0.02 
The sensitivity of 18F with the Inveon PET/SPECT/CT scanner in the geometry previously 
described was measured to be 0.036 ± 0.002 counts/decay.  After correcting for the positron 
yield, this gave an efficiency of 0.037 ± 0.002 counts/positron.  Finally, the count rate linearity 
was fitted with a linear regression, as shown in Figure 44, with R2 = 0.9984.  These values are 
comparable to those measured by Visser and colleagues on the Inveon system.70 
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Figure 44: The count rate linearity of 18F was assessed by plotting the observed counts versus the known activity in 
the phantom. The 16.9 mL phantom was imaged with a small animal PET scanner for 5 minutes at each activity with 
a 350 - 650 keV energy window. 
5.1.5. 89Zr Characterization 
89Zr has 78.4 hour half-life, a positron yield of 22.7%, and mean positron energy of 395.5 keV. 
The PET imaging characteristics of 89Zr were assessed because it has higher positron energy than 
18F, so the change in spatial resolution should be observed.  Additionally, it has a different 
positron yield than 18F, so a different sensitivity should also be measured. The spatial resolution 
of 89Zr measured at the four positions is shown in Table 11. These values were comparable to 
those previously reported by Disselhorst.71 
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Table 11: The full width at half maximum of the reconstructed 89Zr spatial resolution phantom image at different 
offsets from the PET scanner isocenter. 
Position Offset Full width at half maximum (mm) 
0 mm × 0 mm 2.10 ± 0.06 
0 mm × 10 mm 2.11 ± 0.08 
15 mm × 15 mm 2.23 ± 0.09 
20 mm × 20 mm 2.40± 0.11 
The sensitivity of 89Zr with the Inveon PET/SPECT/CT scanner in the geometry previously 
described was measured to be 0.008 ± 0.001 counts/decay.  After correcting for the positron 
yield, this resulted in an efficiency of 0.035 ± 0.005 counts/positron, which was similar to that 
measured for 18F. Finally, the count rate linearity was fitted with a linear regression, as shown in 
Figure 45, with R2 = 0.9807. 
 
Figure 45: The count rate linearity of 89Zr was assessed by plotting the observed counts versus the known activity in 
the phantom. The 16.9 mL phantom was imaged with a small animal PET scanner for 5 minutes with a 350 - 650 
keV energy window. 
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5.1.6. 52Mn Characterization 
52Mn has 5.59 day half-life, a positron yield of 29.6%, and mean positron energy of 241.6 keV. 
The spatial resolution of 52Mn measured at the four phantom bore positions is shown in Table 12.  
The measured values are similar to those reported for 52Mn by Topping.72 
Table 12: The full width at half maximum of the reconstructed 52Mn spatial resolution phantom image at different 
offsets from the PET scanner isocenter. 
Position Offset Full width at half maximum (mm) 
0 mm × 0 mm 1.96 ± 0.08 
0 mm × 10 mm 1.96 ± 0.16 
15 mm × 15 mm 2.01 ± 0.08 
20 mm × 20 mm 2.23± 0.14 
The sensitivity of 52Mn with the Inveon PET/SPECT/CT scanner in the geometry previously 
described was measured to be 0.0104 ± 0.0008 counts/decay.  After correcting for the positron 
yield, this resulted in an efficiency of 0.035 ± 0.003 counts/positron, which was similar to that 
measured for the other imaging radionuclides. Finally, the count rate linearity was fitted with a 
linear regression, as shown in, with R2 = 0.998. 
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Figure 46: The count rate linearity of 52Mn was assessed by plotting the observed counts versus the known activity 
in the phantom.  The 16.9 mL phantom was imaged with a small animal PET scanner for 5 minutes with a 350 - 650 
keV energy window. 
5.2. Hybrid PET/MR Imaging of U87-MG Tumor Bearing Mice 
To demonstrate the multi-modal use of the [52Mn]-MIONs developed in Section 3.2, the [52Mn]-
MION-cRGDs were utilized to image nude mice bearing U87MG xenograft tumors.  The αVβ3 
integrin expression was first characterized using fluorescent anti-body staining and flow 
cytometry.  Then the binding of the [52Mn]-MION-cRGDs to the αVβ3 integrin was demonstrated 
through a solid phase assay. 
5.2.1. Hybrid PET/MRI phantom study 
To observe and compare the PET and MRI signals from [52Mn]-MIONs, a phantom was made 
with 15 vials of known concentrations and activities of [52Mn]-MIONs.  It was MR and PET 
imaged, then resulting PET signal and MR contrast was quantified.  The MRI sequence used to 
image the phantom, was the same described in Section 4.2, and used for all animal MRI studies.  
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Each vials signal and contrast was plotted as a function of the probe concentration.  The MR and 
PET images are shown in Figure 47 and the quantification of the PET and MR signals are shown 
in Figure 48.  The PET signal scales linearly with probe concentration and activity (R2 = 0.9975), 
unlike the MR contrast, which stops increasing at high [52Mn]-MION concentrations.  This 
indicates that the PET signal is better to use for MION concentration quantification than MR 
contrast. 
 
Figure 47: [52Mn]-MION loaded phantom was imaged with MRI and PET.  The known probe concentrations gave 
MR contrast (left) and PET signal (right).  Two different [52Mn]-MIONs are in the phantom.  Low activity (left part 
of the phantom) and high activity (right part of the phantom).  The ringing artefact seen in the MR image is a result 
of the sharp discontinuity between the plastic of the vial and the water in each phantom and the finite number of 
harmonics used in the fourier series in image reconstruction, as known as the “Gibbs phenomenon.” It does not 
affect the ROI values, as long as the ROI covers a large area of the vial. 
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Figure 48: The MR contrast (red) and PET signal (blue) of a [52Mn]-MIONs loaded phantom. The high activity 
[52Mn]-MION vials shown in Figure 47 were quantified.  The PET signal increases linearly with probe 
concentration, unlike the MR contrast which stops increasing at high MION concentrations. 
5.2.2. U87MG tumor model 
The U87MG human primary glioblastoma cell line is known to express αVβ3 integrin and has 
been utilized in previous αVβ3 integrin imaging studies using RGD peptide.73,74,75,76 Parental 
human glioblastoma U87MG cells were obtained from American Type Culture Collection 
(Manassas, VA, USA). The cells were cultured in Eagle's minimum essential medium (EMEM) 
containing 10% FBS, 100 U/ml penicillin, and 100 ug/ml streptomycin.  The cells were 
propagated at 37º Celsius in a 5% carbon dioxide atmosphere. Xenografts were implanted by 
subcutaneous injection of 2.5 million cells into the right shoulder of 6 week old female athymic 
nude mice.   
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Before implantation, the expression of αVβ3 integrin of the U87MG cells was assessed with a 
fluorescent labeled antibody by flow cytometry, as described below: 
(1) 1 ×106 U87MG cells were collected and washed with PBS three times. 
(2) The cells were resuspended in in 100 ul of PBS/BSA/Azide staining buffer and incubated 
with 2 μL of Fc blocker (BD Pharmingen, San Jose, Ca) on ice, to prevent non-specific 
binding of the anti-body. 
(3) The cells were incubated for 20 minutes with 2 μg of human integrin αVβ3 anti-body 
labeled with Alexa Fluor 488 (R&D Systems, Minneapolis, Mn) 
(4) The cells were washed three times with staining buffer. 
(5) The cells were resuspended in 1 ml of staining buffer and analyzed by flow cytometer. 
(6) The fluorescence signal of 50,000 cells was analyzed on a cell by cell basis using 
FACSCalibur (BD Pharmingen, San Jose, Ca). 
After the imaging study, the tumor xenografts were resected. Tumors were cut into small pieces 
and digested using triple enzyme mix in Hank’s balanced salt solution (Life Technologies, Grand 
Island, NY) for 1 hr. The digested tissues were passed through a cell strainer to obtain single cell 
suspension. These cells were stained and analyzed for human integrin αVβ3, as described above. 
This further verified the αVβ3 integrin expression in vivo. Cells were recovered by homogenizing 
the tumor tissue.  In flow cytometery, light scattered by the cell forward (FSC), corresponds to 
cell volume.  Light scattered by the cell to the side (SSC) corresponds to the cell’s inner 
complexity or granularity. During flow cytometry analysis, a gate was created to include the 
relatively large complex living tumor cells, and exclude apoptotic bodies and, in the case of the 
recovered tumor cells, any non-U87MG cells also recovered.  Representative gates are shown in 
Figure 49. 
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Figure 49: The U87MG cells analyzed with flow cytometry were gated to select mainly living U87MG cells, and 
exclude apoptotic bodies and other cells recovered from tumor tissue. 
The result from the flow cytometry analysis of the U87MG cells before implantation is shown in 
Figure 50. The antibody stained cells are compared to unstained cells, and cells incubated with 
and isotype negative control.  The isotype negative control is a fluorescently labeled protein that 
does not have a cellular target, showing the extent of non-specific binding.  MCF-7 human breast 
cancer cells, known not to express αVβ3 integrin, were also used as a negative control to show the 
specificity of the antibody staining. These cells were grown and analyzed in the same fashion as 
the U87MG cells.  The results of the flow cytometry analysis of the U87MG cells recovered 
from the tumor xenografts are shown in Figure 51.  The histogram reveal, an increase in mean 
fluorescent intensity of U87MG cells stained with αVβ3 antibody compared to unstained and 
isotype negative control stain both before implantation and after recovery from tumor tissues.  
This indicates that the αVβ3 integrin is expressed on the U87MG cells in vitro and in vivo.  
Therefore, U87MG tumors were verified as appropriate for molecular imaging studies targeting 
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the αVβ3 integrin. 
 
Figure 50: Flow cytometry results of U87MG and MCF-7 cells before implantation as xenograft tumors in nude 
mice.  U87MG cells show increased fluorescence with the αVβ3 antibody stain compared to unstained and isotype 
negative control stain, indicating that the αVβ3 integrin is expressed on the U87MG cells.  The MCF-7 cells do not 
show a shift in fluorescence intensity, indicating a lack of αVβ3 integrin expression. 
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Figure 51: Flow cytometry results of U87MG cells recovered from xenograft tumors used for the hybrid imaging 
study.  The increased mean fluorescence intensity of the αVβ3 antibody stained cells compared to the unstained and 
isotype control stained cells indicates that the U87MG cells are expressing αVβ3 integrin in vivo. 
5.2.3. Assessment of αVβ3 Integrin Binding 
In order to evaluate the binding of cRGD and cRGD conjugated nanoparticles to the αVβ3 
integrin in isolation, a solid phase binding assay was developed.  Purified αVβ3 integrin 
(eBioscience, Inc., San Diego, CA) was coated onto flexible 96 well plates as described below: 
(1) The wells of a flexible 96 well plate were coated with 100 μL of recombinant human 
integrin αVβ3 in duplicates at various integrin concentrations (4 μg/mL, 2 μg/mL, 1 
μg/mL, and uncoated) dissolved in one of three coating buffers (PBS, 1 mM MgCl2 in 
PBS, or Tris NaCl Buffer). 
(2) The plate was sealed and incubated overnight at 4ºC. 
(3) The unbound integrin containing buffer was removed from the wells. 
(4) The wells were washed three times with wash buffer (0.005% Tween 20 in PBS (pH7.2-
7.4). 
(5) The wells were loaded with 220 μL of blocking buffer (3% BSA in PBS) and incubate at 
room temperature for 2 hours. 
(6) The blocking buffer was discarded and the wells were washed three times with wash 
buffer. 
To determine the effectiveness of each coating buffer and integrin concentration sufficient to 
coat the wells and to establish the binding of cRGD with αVβ3 integrin, the wells were then 
loaded with biotinylated cRGD (Peptides International, Louisville, KY).  This was followed by 
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incubation with StreptavidinPE (eBioscience, Inc., San Diego, CA), which is a fluorescent dye 
with established binding with biotin.  This process is described below: 
(1) The wells were loaded with an excess (100 μL of 1μg/mL) of biotinylated cRGD for 1 
hour at 37ºC prepared in PBS containing 0.1% BSA. 
(2) The biotinylated cRGD was aspirated out and the wells were washed three times with 
wash buffer. 
(3) The wells were then incubated with 100 μL of 0.6 μg/mL of StreptavidinPE for 30 min at 
room temperature.  
(4) The wells were aspirated and washed them three times with wash buffer. 
(5) With 100 μL of PBS loaded in each well, the fluorescent signal of the StreptavidinPE 
remaining in the wells was measured with a fluorescence microplate reader. 
The fluorescent intensity of each well was measured to verify the binding of cRGD with αVβ3 
integrin.  In all cases, greater fluorescent signal was detected from αVβ3 integrin wells compared 
with the un-coated negative control wells (1000 ± 350 counts).  The results are shown in Figure 
52.  Based on these results, all further wells were coated with αVβ3 integrin at 1 μg/mL dissolved 
in 1 mM MgCl2 in PBS solution. 
 
Figure 52: The StreptavidinPE fluorescence signal from wells coated with different concentrations of integrin and 
different coating buffers.  After coating, wells were incubated with biotinylated cRGD and then StreptavidinPE. 
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Next, the binding of cRGD conjugated nanoparticles was evaluated directly by incubating 
integrin coated wells with known amounts of 52Mn-MION-cRGD.  Untargeted 52Mn-MION was 
used as a negative control to assess the non-specific nanoparticle binding and the method is 
described below: 
(1) 42 wells were coated with αVβ3 integrin as previously described. 
(2) Wells were incubated with seven concentrations of cRGD conjugated and untargeted 
52Mn-MIONs ranging from 120 μg/mL to 0 μg/mL in triplicate. 
(3) Wells were washed three times with PBS. 
(4) Wells were cut from the plate, placed into test tubes, the gamma emission was counted 
and plotted versus the known incubation activity. 
The results of the solid phase binding assay, shown in Figure 53, indicated that the 52Mn-MION-
cRGD had greater binding than the untargeted 52Mn-MION.  The uncertainty of the values was 
evaluated by the standard deviation of the triplicate measurement.  The greater uptake of the 
cRGD targeted MIONs indicates the binding of the 52Mn-MION-cRGD with the αVβ3 integrin. 
 
Figure 53: Solid phase binding assay of conjugated and untargeted 52Mn-MIONs with wells coated with αVβ3.  The 
greater uptake of the cRGD targeted MIONs indicates the binding of the 52Mn-MION-cRGD with the αVβ3 integrin. 
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5.2.4. PET Results 
[52Mn]-MION-cRGDs were utilized to image nude mice bearing U87MG xenograft tumors.  The 
tumors were implanted as described in Section 5.2.2, and grown for 10 days.  The tumors were 
110 ± 40 mg in mass at the time of the imaging study, based on caliper measurements.  Tumor 
bearing mice were split into three group, based on the surface coating of [52Mn]-MIONs that 
were administered via tale-vein injection and in one group based on the blocking cRGD dose 
used.  Three mice were injected with untargeted [52Mn]-MION (162±7 μCi, 110±5 mg of Fe), as 
an untargeted control.  Three mice were injected with [52Mn]-MION-cRGD (125±4 μCi, 86±3 
mg of Fe), for targeted imaging.  And finally two mice were injected with [52Mn]-MION-cRGD 
(115±3 μCi, 79±2 mg of Fe) and a blocking dose of 1.3 mg of free cRGD.  During the 
bioconjugation reaction, 100 μg of cRGD is used for an entire synthesis, therefore the blocking 
dose should be at least 50-100 times the cRGD concentration present on the injected [52Mn]-
MION-cRGDs. During the study, one mouse from the second cohort and one mouse from the 
third cohort died from the extensive use of anesthetic needed for the multiple imaging sessions.  
Mice were MR imaged before injection.  At 3 hours and 24 hours after MION injection, each 
mouse was MR and PET/CT imaged.  Each mouse has a customized pallet with an outline of the 
mouse for increased reproducibly during image setup, as shown in Figure 54. 
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Figure 54: Each mouse in the imaging study had an individualized pallet that was used in both the MR and PET 
scanners.  An outline of the mouse was drawn to increase positioning reproducibility, but because of the different 
shaped nose cones of the scanners, positioning was not entirely reproduced. 
After the imaging study, PET, CT, and MRI images were initially rigidly co-registered for 
analysis.  Regions of interest (ROIs) were contoured over the tumor, liver, kidneys, and brain of 
each mouse, and the %ID/g from the PET scans was calculated as described below: 
(1) PET images were reconstructed using the OSEM3D-MAP iterative algorithm.  By 
utilizing the phantom measurements described in Section 5.1, the scanner was calibrated 
following the scanner manufacturers protocol, and the voxel values were given in units of 
nCi/cm3. 
(2) ROIs were drawn over the tumor, liver, kidney, and brain of each mouse.  The average 
signal (SROI) in nCi/cm3 of each ROI was calculated. 
(3) The injected dose (ID) in μCi that was measured at the time of injection was decay 
corrected to the start of the scan to give the decay corrected injected dose (IDdecay).  
(4) The %ID/g was calculated using equation 11.  The assumption was made that 1 cm3 of 
soft tissue had a mass of 1 g. 
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Note that the tumor, liver, brain contours were made with only the CT image, while the kidneys 
were contoured with both CT and MR image input.  The image quantification of %ID/g of the 
tumors from all cohorts is shown in Figure 55.  Values are average %ID/g of all voxels within 
the ROI averaged across multiple mice. 
 
Figure 55: The %ID/g of 52Mn-MION, quantified through ROI analysis of PET images.  Contours were drawn 
based on co-registered CT and MR images.  U87MG xenograph tumor bearing mice were tail-vein injected with 
untargeted [52Mn]-MION (162±7 μCi, 110±5 mg of Fe), [52Mn]-MION-cRGD (125±4 μCi, 86±3 mg of Fe), or 
[52Mn]-MION-cRGD (115±3 μCi, 79±2 mg of Fe) and a blocking dose of 1.3 mg of free cRGD, and PET and MRI 
scanned at different time points. 
Higher PET signal is measured for cRGD targeted MIONs compared to the untargeted MIONs at 
both 3 hours and 24 hours.  This indicates that MION uptake in the tumor is increased through 
nanoparticle cRGD targeting. The blocked 52Mn-MION-cRGD tumor uptake is similar to the 
unblocked at 3 hours, but decreases at 24 hours.  This indicates only a partial blocking effect, 
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which is difficult to explain, considering the large blocking dose. The increased clearance of 
52Mn-MION-cRGD when administered with a blocking dose of free cRGD indicates some 
specific nanoparticle binding. 
Uncertainty values are from the standard deviation of %ID/g.  The %ID/g values of all four 
tissues from each cohort are shown in Figure 56, Figure 57, and Figure 58.  %ID/g values are 
also shown in Table 13.  For all 52Mn-MION injections, regardless of targeting, the greatest 
uptake is in the liver.  This is likely due to the uptake of nanoparticles by Kupffer cells and other 
macrophages in the liver as part of the reticuloendothelial system.  The low uptake in the brain 
indicates that the nanoparticles are unable to cross the blood-brain barrier. Finally, the moderate 
uptake in the kidneys may indicate that some of the radionuclide is undergoing renal clearance. 
 
Figure 56: %ID/g of various tissues from ROI analysis of PET image data.  Mice were injected with untargeted 
52Mn-MIONs (162±7 μCi, 110±5 mg of Fe) and show high uptake in the liver at both time points.  Tumor and brain 
accumulation is low, while kidney uptake is moderate. 
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Figure 57: %ID/g of various tissues from ROI analysis of PET image data.  Mice were injected with 52Mn-MION-
cRGDs (125±4 μCi, 86±3 mg of Fe) and show high uptake in the liver at both time points.  Brain accumulation is 
low, while kidney uptake is moderate.  Tumor uptake is increased compared to the untargeted nanoparticles. 
 
Figure 58: %ID/g of various tissues from ROI analysis of PET image data.  Mice were injected with 52Mn-MION-
cRGDs (115±3 μCi, 79±2 mg of Fe) and a blocking dose of 1.3 mg of free cRGD and show high uptake in the liver 
at both time points.  Brain accumulation is low, while kidney uptake is moderate.  Tumor uptake is initially high, but 
decreases at the 24 hour time. 
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Table 13: The %ID/g values of various tissues as measured with ROI analysis of PET data for 52Mn-MION injected 
tumor bearing mice. 
Nanoparticle 
Injection 
Tissue 3 Hour Uptake 
(%ID/g) 
24 Hour Uptake 
(%ID/g) 
Untargeted 52Mn-
MION 
Tumor 
Liver 
Kidneys 
Brain 
1.4±0.2 
26±3 
5±3 
0.8±0.3 
1.3±0.2 
24±3 
3±1 
0.7±0.3 
52Mn-MION-cRGD Tumor 
Liver 
Kidneys 
Brain 
2.7±0.5 
26±5 
4±2 
1.5±0.8 
3.1±0.4 
23±3 
4±2 
0.34±0.08 
52Mn-MION-cRGD 
+ blocking cRGD 
Tumor 
Liver 
Kidneys 
Brain 
2.8±1.6 
28±4 
4±2 
0.8±0.4 
1.3±0.4 
26±4 
2±1 
0.4±0.3 
The PET/CT imaging data collected is presented below, in Figure 59 through Figure 64, as 
selected sagittal and coronal slices of the mice, chosen to show the tumor, liver, and brain.  
Thresholding, windowing, and leveling are consistent through all images. 
 
Figure 59: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with untargeted 52Mn-
MION (162±7 μCi, 110±5 mg of Fe) 3 hours after injection.  The left coronal image shows the right shoulder tumor 
(arrow).  The right sagittal view shows high signal from the liver (arrow). 
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Figure 60: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with untargeted 52Mn-
MION (162±7 μCi, 110±5 mg of Fe) 24 hours after injection.  The left coronal image shows the right shoulder 
tumor (arrow).  The right sagittal view shows high signal from the liver (arrow). 
 
Figure 61: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with cRGD targeted 52Mn-
MION (125±4 μCi, 86±3 mg of Fe) 3 hours after injection.  The left coronal image shows the right shoulder tumor 
(arrow).  The right sagittal view shows high signal from the liver (arrow). 
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Figure 62: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with cRGD targeted 52Mn-
MION (125±4 μCi, 86±3 mg of Fe) 24 hours after injection.  The left coronal image shows the right shoulder tumor 
(arrow).  The right sagittal view shows high signal from the liver (arrow).
- 
Figure 63: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with cRGD targeted 52Mn-
MION (115±3 μCi, 79±2 mg of Fe) 3 hours after injection.  The left coronal image shows the right shoulder tumor 
(arrow).  The right sagittal view shows high signal from the liver (arrow). 
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Figure 64: Selected PET/CT images of U87MG tumor bearing mouse tail vein injected with cRGD targeted 52Mn-
MION (115±3 μCi, 79±2 mg of Fe) 24 hours after injection.  The left coronal image shows the right shoulder tumor 
(arrow).  The right sagittal view shows high signal from the liver (arrow). 
As a non-MION control, 52MnCl2 was injected into a non-tumor bearing mouse (73 μCi) and 
PET imaged 24 hours after injection.  The resulting PET images, shown in Figure 65, show 
considerable liver uptake, similar to the 52Mn-MIONs, but also large kidney signal, unlike the 
52Mn-MIONs.  After the imaging, the mouse was sacrificed, and the %ID/g of each tissue was 
measured through gamma emission, as described in Section 4.1.  The results of this 
biodistribution study are shown in Figure 66, and parallel the PET data, with large uptake in the 
kidneys and liver.  The differences in the PET data from 52MnCl2 injected mouse and the 52Mn-
MION injected mice, indicate that the nanoparticle construct is affecting the distribution and 
uptake of 52Mn in vivo.  Also, the difference in kidney signal between the 52MnCl2 injected 
mouse and the 52Mn-MION indicate that the 52Mn is staying with the 52Mn-MION after injection. 
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Figure 65: PET/CT image of 52MnCl2 (73 μCi) injected mouse.  The left coronal view shows high liver (arrow) 
signal, while the right sagittal view also shows considerable kidney signal. 
 
Figure 66: Biodistribution of a 52MnCl2 injected mouse 24 hours post-injection.  A nude mouse was tail-vein 
injected with 73 μCi of  52MnCl2 and sacrificed after 24 hours.  The tissues were collected and weighed and the 
%ID/g was calculated for various tissue. The high uptake in the liver and kidneys parallels the PET data, shown in 
Figure 65. 
5.2.5. MRI Results 
In the 52Mn-MION-cRGD imaging study, MR images were collected along with the PET data, as 
described in Section 5.2.4.  Mice were also imaged before injection.  The MR imaging protocol 
used was the same FISP sequence that was described and utilized in Section 4.2.  Selected 
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coronal images below show the tumor of each injected mouse before, 3 hours after, and 24 hours 
after injection. 
 
Figure 67: Select images of untargeted 52Mn-MION injected (162±7 μCi, 110±5 mg of Fe) mouse before (left), 3 
hours after (middle), and 24 hours after (right) injection.  The mouse was imaged with a Fast Imaging with Steady 
State Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of 
scans averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue 
arrows indicate the tumor, the red arrows indicate the liver, and the yellows arrows indicate the kidneys. 
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Figure 68: Select images of cRGD targeted 52Mn-MION injected (125±4 μCi, 86±3 mg of Fe) mouse before (left), 3 
hours after (middle), and 24 hours after (right) injection.  The mouse was imaged with a Fast Imaging with Steady 
State Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 4.7 ms and number of 
scans averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted images.  The blue 
arrows indicate the tumor,  the green arrows indicate the brain.  The liver and kidneys are not visible in this image. 
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Figure 69: Select images of cRGD targeted 52Mn-MION and blocking free cRGD injected (115±3 μCi, 79±2 mg of 
Fe) mouse before (left), 3 hours after (middle), and 24 hours after (right) injection.  The mouse was imaged with a 
Fast Imaging with Steady State Precession (FISP) sequence with a repeat time (TR) of 9.4 ms and echo time (TE) of 
4.7 ms and number of scans averaged (NSA) of 4.  A flip angle (FA) of 35º was used to achieve T2*/T1 weighted 
images.  The blue arrows indicate the tumor, the red arrows indicate the liver, and the yellows arrows indicate the 
bladder.  The kidneys are not visible in this image. 
The % contrast is measured as the percent signal decrease of the ROI compared with the ROI of 
the same tissue imaged before injection. After image acquisition, the MR images were rigidly co-
registered and ROIs were drawn on the tumor, liver, kidney, and brain tissues.  The mean MR 
signal from each ROI was used to calculate the contrast induced by the MION injections in each 
tissue.  The contrast measured in the tumors is shown in Figure 70.  A significantly larger 
amount of contrast is only seen in the 52Mn-MION-cRGD injected at 3 hours after injection, 
compared to the untargeted and cRGD blocking injections. The quantification of MR contrast of 
the other tissues is shown below as % contrast in Figure 71, Figure 72, and Figure 73. 
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Figure 70: The % contrast induced in tumor tissue by 52Mn-MION injection, quantified through ROI analysis of 
MR images.  Contours were drawn based on co-registered the MR images.  U87MG xenograph tumor bearing mice 
were tail-vein injected with untargeted [52Mn]-MION (162±7 μCi, 110±5 mg of Fe), [52Mn]-MION-cRGD (125±4 
μCi, 86±3 mg of Fe), or [52Mn]-MION-cRGD (115±3 μCi, 79±2 mg of Fe) and a blocking dose of 1.3 mg of free 
cRGD. 
 
Figure 71: The % contrast induced by untargeted 52Mn-MION injection (162±7 μCi, 110±5 mg of Fe) in specific 
tissues measured with ROI analysis.  The % contrast is measured as the percent signal decrease of the ROI 
compared with the ROI of the same tissue imaged before injection. 
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Figure 72: The % contrast induced by cRGD- 52Mn-MION injection (125±4 μCi, 86±3 mg of Fe) in specific tissues 
measured with ROI analysis.  The % contrast is measured as the percent signal decrease of the ROI compared with 
the ROI of the same tissue imaged before injection. 
 
Figure 73: The % contrast induced by cRGD- 52Mn-MION (115±3 μCi, 79±2 mg of Fe) and blocking free cRGD 
injection in specific tissues measured with ROI analysis.  The % contrast is measured as the percent signal decrease 
of the ROI compared with the ROI of the same tissue imaged before injection. 
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5.2.6. Co-registered Hybrid PET/MRI Results 
Finally, PET/CT imaging results were rigidly co-registered with MR results, based on 
landmarks, specifically the skull, spine, and liver.  The registration error was not evaluated, 
because the structures being co-registered were not ridged, and such analysis was not necessary 
for this study.  Selected slices of the hybrid images are shown below in Figure 74, Figure 75, and 
Figure 76.  PET signal matches with areas of MR contrast, especially in the liver.  The right 
shoulder tumors show only small MR contrast and PET signal.  The quantification of probe 
concentration from MR data was found not to be a robust method, as shown in Section 4.4.2, so 
side by side comparisons of PET signal based %ID/g and MR % contrast based %ID/g were not 
plotted. 
 
Figure 74: Coronal images of an untargeted 52Mn-MION injected (162±7 μCi, 110±5 mg of Fe) mouse 24 hours 
after injection.  The MR image of the mouse before injection is on the far left, while the MR image of the mouse 24 
hours after injection is on the left middle.  The PET scan of the mouse after 24 hours is on the middle right, while 
the co-registered pre-injection MR image with the PET image is on the far right. 
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Figure 75: Coronal images of a 52Mn-MION-cRGD (125±4 μCi, 86±3 mg of Fe) injected mouse 24 hours after 
injection.  The MR image of the mouse before injection is on the far left, while the MR image of the mouse 24 hours 
after injection is on the left middle.  The PET scan of the mouse after 24 hours is on the middle right, while the co-
registered pre-injection MR image with the PET image is on the far right. 
 
Figure 76: Coronal images of an 52Mn-MION-cRGD (115±3 μCi, 79±2 mg of Fe) with blocking cRGD injected 
mouse 24 hours after injection.  The MR image of the mouse before injection is on the far left, while the MR image 
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of the mouse 24 hours after injection is on the left middle.  The PET scan of the mouse after 24 hours is on the 
middle right, while the co-registered pre-injection MR image with the PET image is on the far right. 
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Chapter 6 
6. Summary and Conclusion 
A synthetic method has been developed for the intrinsic incorporation of 59Fe into SPION MRI 
contrast agents.  These nanoparticles have been coated with a multidentate poly-ethylene-glycol 
ligand for water solubility and biocompatibility. The physical characteristics, including 
hydrodynamic size, inorganic core size, surface charge, and relaxivity have been measured.  
Additionally, the in vivo biodistribution of the untargeted SPIONs has been characterized with 
MRI and the gamma emission of 59Fe-SPIONs. 
After this was accomplished, 52Mn was produced with a small hospital based cyclotron.  It was 
chemically separated and purified, then incorporated into 52Mn-MIONs.  The gamma spectrum 
of 52Mn was characterized. Additionally, the PET imaging characteristics of sensitivity, spatial 
resolution, and count-rate linearity were evaluated for 52Mn in a small animal PET scanner. 
Finally, the 52Mn-MION surface ligands were modified with the addition of cRGD, an imaging 
peptide.  The binding of cRGD and 52Mn-MION-cRGD with αVβ3 integrin was confirmed with 
solid phase αVβ3 integrin assay. Then 52Mn-MION-cRGD was utilized in a hybrid PET/MRI 
study with U87MG tumor xenograft bearing mice.  Tumor PET signal was increased in 52Mn-
MION-cRGD injected mice, compared with untargeted 52Mn-MION injected mice. 
 117 
 
6.1. Radio-intrinsic superparamagnetic nanoparticles 
The incorporation of 59Fe into the SPION structure was accomplished with two strategies.  The 
first included the 59Fe in the initial reagents and utilized the radionuclide throughout the 
nanoparticle structure.  The second approach added the radionuclide to already formed SPION 
cores, to form a shell that included the radioactive iron.  This allowed for increased radionuclide 
yield and reduced starting reagents.  Either approach resulted in nanoparticles with similar 
relaxivity as natural nanoparticles synthesized with similar strategies.  This indicates that the 
incorporation of 59Fe within SPION nano-crystal structures was accomplished without reducing 
their relaxivity, and thereby lessening their usefulness as hybrid imaging agents.  Initially, a 
strategy similar to the 59Fe core/shell incorporation was developed for 52Mn incorporation.  The 
resulting core/shell MION productions yielded nanoparticles with inconsistent radionuclide 
incorporation efficiency and MR characteristics.  Therefore, an incorporation strategy similar to 
the first single step 59Fe incorporation was developed.  In this approach, 52Mn was included in 
the initial reagents for the MION core and utilized throughout the nano-crystal.  This resulted in 
consistent 52Mn incorporation efficiency and MR contrast properties, as well as a nanoparticle 
agent appropriate for the subsequent hybrid PET/MR imaging studies. 
6.2. Hybrid PET/MRI 
The 52Mn-MIONs were characterized in both PET and MRI scanners with a phantom study.  
This demonstrated the multi-modal signal originating from the hybrid nanoparticles.  Then the 
52Mn-MIONs were utilized in vivo for a hybrid PET/MRI study imaging xenograft tumor 
bearing mice.  PET and MRI data was collected and analyzed showing the multimodal use of the 
radio-intrinsic hybrid PET/MRI nanoparticle. 
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Chapter 7 
7. Further Work 
The successful development of cRGD targeted 52Mn-MIONs lends itself to a number of future 
uses.  cRGD is a targeting peptide shown to bind with the αVβ3 integrin, which is associated with 
angiogenesis.  The angiogenesis is necessary for tumor development and progression and this 
probe is a candidate for studying angiogenesis in other cancer models.  U87MG tumors were 
utilized in this project, but other cell lines that do not themselves express αVβ3 integrin can be 
used.  In these imaging studies, the endothelial cells growing blood vessels to support the tumors 
would be targeted.  Additionally, orthotopic tumor models can be utilized to more realistically 
recreate the tumor micro-environment found in the clinic.77,78  The 52Mn-MION-cRGDs can also 
be used in imaging trails to validate anti-vascular therapies for cancer.79  Changes in the probe 
uptake could be related to tumor response to the anti-vascular drugs. 
7.1. Future direction for 52Mn 
Ionic 52Mn2+ has a number of possible uses for follow up studies.  As a result of the 5.591 day 
half-life of 52Mn, it can be used to study the metabolism and pharmacokinetics of manganese in 
intact organisms.  Previous work has shown that 52Mn2+ is taken up by bones, similar to 18F, 
which indicates that it could be used in bone imaging application that last weeks, as opposed to 
18F which is only used for shorter studies.80  Additionally, the high energy gamma emission of 
52Mn may provide cascade background in PET imaging applications.  Further work could correct 
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for this by gathering data on events detected by the PET scanner at energies above the normal 
PET window and subtracting this background. 
7.2. Future direction for [52Mn]-MION 
The [52Mn]-MION imaging agent has considerable possibilities for future development.  An 
imaging study using a hybrid PET/MRI scanner would allow for better co-registration of PET 
and MR data and a possible statistical analysis on a pixel by pixel basis of the correlation 
between MR contrast and PET signal.  In this work, cRGD was utilized for targeting, but the 
surface coating is appropriate for modification with a wide variety of potential targeting 
molecules.  J591, an anti-prostate specific membrane antigen (PSMA) antibody, could be 
conjugated to target and image PSMA expression in prostates and prostate cancers.81  Another 
option is the use of Herceptin, an anti-her2/neu monoclonal antibody, which has been used to 
target and image breast cancer cell lines.82 The MIONs and SPIONs developed in this project 
showed considerable uptake in the liver.  This reduced their effectiveness as targeted imaging 
agents, as the probes were not available to the bind with the targets expressed on tumor cells, if 
they were sequestered in the liver.  While this project attempted to reduce this problem with 
different coating strategies, further work could explore the development of other organic ligands 
to reduce the liver uptake and increase the nanoparticles bio-availability.  Specifically, a 
zwitterionic coating could be investigated to increase blood circulation.   
As mentioned in Section 3.5, the size range of the nanoparticles synthesized in this method is not 
totally reproducible.  This variability is not so great that it prohibits in vivo application of these 
nanoparticles, because the size variation (2-15 nm) falls within the range of nanoparticles that 
can circulate within intact vasculature.  As shown in this work the [52Mn]-MION can be imaged 
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with both PET and MRI.  PET has excellent probe sensitivity and quantification, but has only 
moderate spatial resolution.  The spatial resolution of MRI is stronger, but MR quantification of 
SPIONs and MIONs is difficult. A hybrid reconstruction could be developed from PET/MRI 
scans of the [52Mn]-MION in the future, which utilized the spatial information from the MR 
contrast and the probe quantification from the PET signal to create a more detailed probe map 
than is available from each modality separately. Finally, the 52Mn-MION platform can be 
utilized to evaluate MIONs and SPIONs in a research capacity. The initial pharmacokinetics, 
degradation, and final endpoint of the MION components can be characterized in vivo with the 
PET signal as part of the validation of different non-radioactive MIONs that are developed for 
clinical application. 
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